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ABSTRACT 
 
The aim of this cross-sectional study was to determine the difference in development 
(cognition; receptive and expressive language; and fine and gross motor) of Human 
Immunodeficiency Virus (HIV) -exposed infected (HEI) infants with the development of 
HIV-exposed but uninfected (HEU) infants using the Bayley Scales of Infant and 
Toddler Development, Third Edition (BSID-III).  Sixty infants were enrolled in the 
study; 32 (53.33%) HEU infants and 28 (46.67%) HEI infants.  The two groups were 
well-matched for infant demographics, anthropometry at birth, maternal demographics, 
as well as socioeconomic status.  Statistically significant differences were found in 
anthropometry and development between the HEI and HEU group.  The HEI infants 
had malnutrition, were stunted and had smaller head circumferences than HEU 
infants.  The BSID-III showed that the mean developmental delay for the HEI group 
was approximately two months below their mean chronological age for all scales 
(cognitive; receptive and expressive communication; and, fine and gross motor age).  
The HEI group showed that 64.29% had cognitive delay, 60.71% had language delay 
and 53.57% had motor delay, all of which was significantly different from the 
development of the HEU group for all domains (p<0.001).  In addition to using the 
BSID-III, the majority of mothers were able to correctly indicate whether their child was 
developing at the same, or at a slower rate of development than children of the same 
age.  This study demonstrates that infants who are HIV-exposed and infected are at 
risk of developmental delay. 
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CHAPTER 1: INTRODUCTION 
 
Sub-Saharan Africa accounts for two-thirds (approximately 22 million people) of the 
global HIV population (UNAIDS, 2009).  Of that, women account for 60% of all HIV 
infections in this region (UNAIDS, 2009).  In sub-Saharan Africa the primary mode of 
transmission of HIV is through heterosexual intercourse, therefore the majority of 
these women will be of child-bearing age (15-49 years).  In 2009, Zimbabwe was 
deemed to be one of 25 countries with the largest number of pregnant women living 
with HIV (UNAIDS, 2010), where Harare had an HIV prevalence of 10-24.9% for 
pregnant women (UNAIDS, 2009).  Pregnant women living with HIV expose their 
infants to HIV during gestation, the perinatal period and/or while breastfeeding.  This is 
the second most important mode of transmission in Zimbabwe (UNGASS, 2009).  
Infants who are born to HIV-positive mothers are referred to as being HIV-exposed.   It 
is estimated that more than 30% of HIV-exposed infants are HIV-positive when there 
has been no intervention (Sharland and Bryant, 2009; Dabis, et al., 1993; Boylan and 
Stein, 1991).  In sub-Saharan Africa, Mother-to-Child-Transmission of HIV (MTCT) 
accounts for more than 90% of all paediatric HIV-cases (UNAIDS, 2010).   
 
HIV is a neurotrophic and neurotoxic virus causing detrimental neuropathological 
changes resulting from both direct and indirect effects of the virus on the central 
nervous system (CNS) (Mitchell, 2006; Albright, et al., 2003; Miller, 2002; Tardieu, 
1998; Schmitt, et al., 1991).  These changes manifest as physical and cognitive 
impairments, which adversely affect function.  The effect of HIV on an immature CNS 
(as in the case of vertically-infected infants) is injurious to a greater extent where 
neurological impairments occur in 15-40% of all cases (Msellati, et al., 1993).  
Significant delays in cognitive, language and motor development are observed in 
these children (Abubakar, et al., 2009; Potterton, et al., 2009; Baillieu and Potterton, 
2008; Van Rie,  et al., 2008; Lindsey, et al., 2007; Foster, et al., 2006; Blanchette, et 
al., 2001; Drotar, et al., 1997; Belman, et al., 1996; Pollack, et al., 1996; Belman, et 
al., 1994) due to the inability of the immature CNS to cope with the destructive nature 
of HIV.  Perinatal infection occurs at a time when an infant’s CNS is going through a 
rapid process of myelination which is synonymous with the most substantive brain 
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development (Willen, 2006).  Despite the above-mentioned evidence of developmental 
delay in children infected with HIV through vertical infection, no studies to date have 
looked at cognition, language and motor development in Zimbabwean infants. 
 
ART has had a tremendous effect in reducing the prevalence of MTCT and decreasing 
mortality due to suppression of the HIV viral load (UNAIDS, 2010).  This has given 
way to improvements in length of life and thus changed the outlook for people living 
with HIV from being a terminal disease, to that of a chronic illness (Robertson, et al., 
2008; Gortmaker, et al., 2001). However it has been reported that despite the 
introduction of ART, the CNS effectively harbours the virus by means of an 
impermeable blood-brain barrier to the majority of available classes of ARVs (Miller, 
2002).  The limited access of ARVs into the CNS provides poor therapeutic levels to 
suppress the virus and so it continues to negatively manifest itself (Jaspan, et al., 
2008; Eley and Nuttall, 2007; Lindsey, et al., 2007).  The implications of extended life 
through ART do not equate to improved quality of life when living with neurological 
impairment secondary to HIV-related neuronal damage. 
 
Problem Statement 
Cognitive, language and motor development of children-exposed to HIV have not 
been studied in Zimbabwe.  National efforts to minimise the effect of HIV in children 
include the provision of ARVs although paediatric roll-out is still limited.  In addition to 
this, national objectives primarily focus on prevention and life-saving measures.  
However, this does not necessarily lead to improved quality of life for those children 
already infected with HIV, and living with neurological impairment. 
 
Aim of Study 
The aim of the study was to determine the difference in development (cognition; 
receptive and expressive language; and fine and gross motor) of HIV-
exposed infected infants (i.e. infants who are born to HIV-positive mothers and are 
themselves infected) with the development of HIV-exposed but uninfected infants. 
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Objectives of the Study 
 To measure height, weight and head circumference of HIV-exposed infected 
infants and HIV-exposed uninfected infants. 
 To assess and describe cognitive, receptive and expressive language, fine and 
gross motor abilities in HIV-exposed infected infants with that of HIV-exposed 
uninfected infants. 
 
Significance of the Study 
There has been no research in Zimbabwe that has looked at development in HIV-
exposed infants and so this problem remains unquantifiable.  This study describes 
cognitive, language and motor development in a sample of Zimbabwean infants who 
were exposed to HIV through MTCT. 
 
Research in this field may highlight gaps in the management of children who are 
experiencing developmental delay, not only those who are HIV-infected.  An 
expansion of services may include access to physiotherapy, introduction of pre-
schools for early cognitive stimulation, and possibly an expansion of ARVs to include 
more efficacious regimens for those who are HIV-positive and vulnerable to HIV-
related neuropathology. 
 
Finally, there is limited available research that has looked to minimise confounding 
cofactors that affect development as a result of neurological insult (orphan hood; 
institutionalisation; exposure to recreational drugs; maternal factors; neurological 
damage associated with pregnancy, labour and delivery and breastfeeding; 
socioeconomic status; and/or malnutrition). 
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Conclusion 
Despite other studies being done worldwide on developmental delay in children living 
with HIV, Zimbabwe faces unique challenges that affect those infants who are born to 
HIV-positive mothers.  There have been no studies hitherto looking at these issues 
and therefore the aim of this study was to determine the development of HIV-exposed 
infected infants compared with HIV-exposed but uninfected infants with a view to 
identify any differences in cognitive, language and motor development. 
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CHAPTER 2: LITERATURE REVIEW 
 
This chapter will review the epidemiology of HIV in sub-Saharan Africa with a closer 
look at MTCT in Zimbabwe.  It will then go on to discuss paediatric HIV and 
management in the developing world.  This review will focus mainly on HIV and its 
implications on a child’s development; and so a closer look at HIV and the developing 
CNS will also be made.  Literature from previous studies looking at development of 
children living with HIV will be discussed.  To conclude this section, the risk factors 
that affect early child development (ECD) will also be presented.   
 
Literature was sourced through comprehensive searches on the following databases: 
Medline, Cochrane Collaboration, Pubmed, ScienceDirect and CINAHL.  The following 
are the key words that were used in searches: HIV, children, development, 
encephalopathy, brain development, CNS, HIV vertical transmission. 
 
2.1 Epidemiology 
 
As stated above, sub-Saharan Africa accounts for two-thirds of the global HIV 
population (22.9 million [21 600 000 – 24 100 000] people in 2010).  Globally, 3.4 
million children [3 000 000 – 3 800 000] are living with HIV, more than 90% of whom 
are living in sub-Saharan Africa.  In 2010, women accounted for 59% [56-63%] of all 
HIV infections in this region.  (UNAIDS and WHO, 2011.)  
 
The primary mode of transmission of HIV in sub-Saharan Africa is through 
heterosexual intercourse (UNGASS, 2009), where the majority of women will be of 
child-bearing age (15-49 years).  Adversely, women living with HIV can during 
gestation, the perinatal period and/or while breastfeeding, expose their infants to HIV, 
which can lead to a large number of infants being infected with HIV.  Therefore MTCT 
is the second most important mode of transmission in sub-Saharan Africa.  
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In sub-Saharan Africa, MTCT accounts for more than 90% of all paediatric HIV-cases 
(UNAIDS, 2010).  Infants who are born to HIV-positive mothers are referred to as 
being HIV-exposed.   It is estimated that more than 30% of HIV-exposed infants are 
HIV-positive when there has been no intervention (Sharland and Bryant, 2009; Dabis, 
et al., 1993; Boylan and Stein, 1991).  In 2009, the reported percentage of 
Zimbabwean infants born to HIV infected mothers who are themselves infected was 
30% (UNGASS, 2009), indicating failure of timely access to PMTCT programmes. 
 
In 2009, Zimbabwe was deemed to be one of 25 countries with the largest number of 
pregnant women living with HIV (UNAIDS, 2010), where Harare had a HIV prevalence 
of 10-24.9% of pregnant women (UNAIDS, 2009).  The history of Zimbabwe’s 
unparalleled socio-economical challenges over the past decade has adversely 
affected basic social services in general.  One of these services is ANC which is a 
means of advocating for Provider-Initiated Testing and Counselling for HIV (PITC) to 
effect PMTCT.   It is well-known that PMTCT is dependent on access to ANC, an 
efficacious duration and regimen of ARVs (or ART if the mother is eligible) and skilled 
attendance during labour and delivery (UNAIDS, 2010; Lehman and Farquhar, 2007).  
PMTCT is not accessible to many pregnant Zimbabwean women living with HIV.  In 
Harare, this is because of the following factors: women attending City of Harare clinics 
who wish to register a pregnancy are expected to pay USD30 (this fee was reduced 
from USD50 at the end of 2010); more than half those HIV-positive, pregnant women 
accessing ANC in 2008 were unable to obtain ARVs (UNAIDS, 2010); and it is 
reported that 39% of all births two years prior to 2009 were home-deliveries without 
skilled attendance (ZHDS, 2009).  Zimbabwean infants born to HIV-positive mothers 
are therefore at high risk of acquiring HIV through vertical transmission due to poor 
access to ANC, little or no skilled attendance, and poor duration and regimen of ARVs.   
 
  
 
 
17 
 
2.2 Paediatric HIV 
 
2.2.1 Mother-to-Child Transmission of HIV (MTCT) 
 
MTCT can occur during pregnancy, intrapartum or during breastfeeding (Lehman and 
Farquhar, 2007; Kourtis, et al., 2001; Kuhn and Stein, 1995).  Maternal viral load 
(presence of HIV-RNA in plasma) is a strong independent determinant of the risk of 
vertical transmission (John and Kreiss, 1996).  A high viral load occurs secondary to 
primary infection of HIV (Humphrey, et al., 2010; Dunn and Newell, 1992), advanced 
disease (Fawzi et al, 2001), or drug resistance (WHO, 2011).  Increased risk of vertical 
transmission is also associated with poor maternal nutrition which can lead to impaired 
epithelial integrity of the placenta and lower genital tract (Dreyfuss and Fawzi, 2002). 
 
The third trimester is associated with the highest transmission of HIV in utero primarily 
occurring when HIV crosses the placenta (Lehman and Farquhar, 2007).  However, 
studies have been done which have found HIV in cells found in electively aborted 
foetuses in the first trimester of pregnancy (Lewis, et al., 1990).  Factors that are 
associated with transmission during pregnancy are: maternal genital infections, as well 
as malaria, which can damage the placenta and allow passage of HIV cells (Gumbo et 
al., 2010; ter Kuile, et al., 2004; Bloland, et al., 1995; Inion, et al., 2003); and, gender, 
where female infants are thought to be at double the risk of infection than males 
(Biggar, et al., 2006). 
 
Intrapartum transmission can occur because the infant is exposed to infected maternal 
blood during delivery (Lehman and Farquhar, 2007).  Factors that will influence 
transmission during delivery are: birth complications; invasive procedures; and poor 
mucosal integrity of the delivery route (Lehman and Farqhar, 2007).   
 
Breastfeeding is another method of MTCT (Coutsoudis, et al., 2004).  HIV-1 RNA has 
been found in infected breast milk cells.  Low to high concentrations of HIV-1 RNA is 
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highly correlated with viral load in plasma.  (Rousseau, et al., 2004).  Factors 
associated with transmission are: early mixed-feeding i.e. before six months of age 
when the infant’s gastrointestinal tract is still immature and susceptible to damage 
(Coovardia, et al., 2007), abrupt breastfeeding cessation (WHO, 2010b), and mastitis 
or breast abscess (Gumbo, et al., 2010). 
 
2.2.2 Testing 
 
Infant testing is dependent on knowledge of the mother’s HIV status.  PITC is 
recommended for all infants and children known to have been exposed perinatally or 
those who shown signs and symptoms suggestive of HIV infection (malnutrition or 
tuberculosis).  Children under 18 months of age require virological testing as antibody 
testing will elicit a false-positive result because maternal HIV antibodies persist during 
this period (WHO and UNICEF, 2010).  Ideally, early infant diagnosis through testing 
should be initiated within the first two months of life because 30% of infants will die 
from HIV before their first birthday, 50% by their second birthday (WHO and UNICEF, 
2011).   
 
Testing is extremely important to reduce mortality and morbidity through timely 
provision of ART before clinical disease manifests, as well as to identify HIV-exposed 
but uninfected infants and thus implement prevention strategies such as counselling 
on appropriate infant feeding practices to reduce risk of future infection (through 
breastfeeding), whilst ensuring adequate nutrition and health (WHO, 2011).  HIV-
exposed infants in Zimbabwe now have access to virological testing using the Dried 
Blood Spot (DBS) method, although this service is not available at all sites nationwide.   
 
All children under the age of two years with a confirmed HIV-positive status are eligible 
for ART.  Testing is therefore a very important factor in ensuring that a diagnosis is 
made so that ART can be initiated promptly. 
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2.2.3 Prevention of Mother-to-Child Transmission of HIV (PMTCT) 
 
PMTCT is primarily dependent on a multitude of factors.  The mother’s knowledge of 
her status before or during pregnancy, and/or accessing antenatal clinics where PITC 
is available, can be complicated by a number of factors such as poverty, psychosocial 
issues, and variance in HIV management.  However, if the mother accesses the 
service then PMTCT works to minimise the risks of transmission through: maternal 
ART (if eligible) or ARV prophylaxis to lower her viral load; infant prophylaxis at birth, 
extended through the breastfeeding period; and, safe feeding practices (where 
exclusive breastfeeding is promoted in developing countries) and prescription of co-
trimoxazole at six weeks for breastfed infants.  Table 2.1 shows the Zimbabwean 
guidelines for PMTCT. 
 
Table 2.0 Zimbabwean PMTCT guidelines 
Year 
Implemented 
Preferred 1st Line ART 
(pregnant women eligible 
for ART) 
ARV prophylaxis 
(pregnant women not eligible 
for ART) 
2011 
Tenofovir + Lamuvidine + NVP, or AZT 300mg bi-daily from 14 weeks 
+ sd-NVP in labour +  
AZT 300mg + Lamuvidine 150mg 
bi-daily for seven days 
AZT + Lamuvidine + NVP  
INFANT: NVP daily for six weeks INFANT: Extended NVP 
prophylaxis to cover breastfeeding 
period. 
2009/10 
 AZT from 28 weeks +  
AZT/Lamuvidine in labour and for 
seven days 
 INFANT: sd-NVP 
2008 
 sd-NVP in labour 
 INFANT: sd-NVP 
 
 
20 
 
 
2.2.4 Antiretroviral Therapy (ART) 
 
ART acts on different stages of the HIV life cycle to prevent replication of the virus 
(Simon, et al., 2006).  De Clercq’s review (2010) shows that with 
Azidothymidine/Zidovudine (AZT) being the first antiretroviral drug used 25 years ago, 
ART has advanced significantly to advocate for three or four drugs to be used in a 
triple therapy combination.  In this report, ART will be the term used to denote highly-
active active antiretroviral therapy (HAART), which has been available since 1996 in 
developed countries (De Clercq, 2009), and since 2004 in Zimbabwe for adult 
formulations.  There are now several classes of ARVs which will be discussed briefly 
with regard to those available in Zimbabwe: 
 
 Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nucleotide Reverse 
Transcriptase Inhibitors (NtRTIs) and Non-Nucleoside Reverse Transcriptase 
Inhibitors (NNRTIs) inhibit the enzyme reverse transcriptase; and thus prevent 
HIV-RNA from transcribing itself into HIV-DNA, which effectively prevents 
replication.  NRTIs include AZT, Stavudine, Lamuvidine, and Abacavir.  NtRTIs 
include Tenofovir.  NNRTIs include Nevirapine (NVP) and Efavirenz. 
 
 Protease Inhibitors (PIs) inhibit the enzyme protease.  Protease is necessary 
for the maturation of RNA viral particles (virions).  Inhibiting protease therefore 
prevents virions from maturing into infectious particles and thus slows 
replication of the virus.  Ritonavir and Lopinavir are PIs.  (Simon, et al., 2006). 
 
With regard to PMTCT, ART/ARVs can be given to an HIV-positive mother in 
pregnancy, the intrapartum period and breastfeeding, to reduce the maternal viral 
load, and thus lower the risk of transmission (Volmink, et al., 2007).  The World Health 
Organization (2010) recommends that pregnant women should be started on ART if 
they are eligible (i.e. confirmed HIV-positive status, and, CD4 count is ≤350µl; and/or 
they present with a WHO Clinical Stage of 3 or 4).  ARV prophylaxis should be given 
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to all pregnant women who are not eligible for ART.   ARVs are recommended as 
post-exposure prophylaxis for the infant at delivery and for the entire duration of 
breastfeeding, regardless of the mother’s HIV management (WHO, 2010a). 
 
2.3 The Developing CNS and HIV 
 
HIV is a neurotropic and neurotoxic virus causing detrimental neuropathological 
changes resulting from both direct and indirect effects of the virus on the CNS 
(Mitchell, 2006; Albright, et al., 2003; Tardieu, 1998; Aylward, et al., 1992; Schmitt, et 
al., 1991).  In children, damage to the CNS is mainly due to presence of the virus, and 
not opportunistic infections, as these are rare, occurring in mainly older children and 
largely in adults (Belman, 1992).  An exception is TB meningitis which is commonly 
reported in infants younger than one year (Hesseling, et al., 2009).   
 
The effect of HIV on an immature CNS (as in the case of vertically-infected infants) is 
injurious to a greater extent than in adults, where neurological impairments occur in 
15-40% of all cases (Msellati, et al., 1993) and manifest as progressive or static 
encephalopathy (Van Rie, et al., 2007, Belman, 1997).  The effects of the virus on the 
CNS will differ according to the stage of brain development at time of infection 
(Belman, 1997), and this too, will lead to varying clinical presentations (Belman, 1990).  
As the last trimester of pregnancy is known to be synonymous with rapid brain 
development, children who are infected at this time are likely to show more severe 
CNS disease progression (European Collaborative Study, 1996).  Having said this, 
disease progression of the infant is dependent on the disease stage, CD4 count and 
viral load of the mother (Ioannidis, et al., 2004; Fawzi, et al., 2001).  Presentations of 
HIV encephalopathy generally manifest as physical, language and cognitive 
impairments, which adversely affect function. 
 
Significant delays in cognitive, language and motor development are observed in 
children infected with HIV (Abubakar, et al., 2009; Potterton, et al., 2009; Baillieu and 
Potterton, 2008; Van Rie,  et al., 2008; Lindsey, et al., 2007; Foster, et al., 2006; 
 
 
22 
 
Blanchette, et al., 2001; Drotar, et al., 1997; Belman, et al., 1996; Pollack, et al., 1996) 
due to the inability of the immature CNS to cope with the destructive nature of the 
virus. 
 
This section will look at the neuropathogenesis of HIV and the clinical manifestations 
of the disease on an immature CNS and will attend to the cognitive, language and 
motor deficits that these children suffer. 
 
2.3.1 Neuropathogenesis 
 
HIV-1 is known to enter the CNS as early as the tenth day after primary infection 
(Powderly, 2000; Davis, et al., 1992) chiefly by infecting blood monocytes, 
macrophages and T lymphocytes which all contain CD4 receptors (Albright, et al., 
2003; Liu, et al., 2000).  This is known as the ‘Trojan-Horse’ hypothesis (Peluso, et al., 
1985) where the infected cells cross the blood-brain barrier (BBB) and/or the 
cerebrospinal fluid (CSF) brain barrier (Albright, et al., 2003).  Ironically, it is these 
structures that prevent ART from permeating efficaciously into the CNS and effectively 
halting viral replication and preventing the development of a drug-resistant, mutant 
virus (Jaspan, et al., 2008; Eley and Nuttall, 2007; Lindsey, et al., 2007; Miller, 2002).   
 
HIV can remain in the nervous system due to this notion that the CNS (by means of its 
barriers) is a viral reservoir (Epstein and Gendelman, 1993).  In this haven the virus is 
known to replicate, thereby causing direct damage to the neural tissue of the CNS 
(Grovit-Ferbas and Harris-White, 2010).  The virus then goes on to infect parenchymal 
microglia and perivascular monocyte-derived macrophages (Wiley, et al., 1986), as 
well as astrocytes and neurons in paediatric infection (Tornatore, et al., 1994).  Unlike 
the adult disease, astrocytes are infected (Tornatore, et al., 1994) which leads to poor 
oligodendrocyte function in the production of myelin (Ishibashi, et al., 2006), hence 
retarded or absent myelination.   
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Secondary effects occur, where the infection of these cells triggers a chronic 
inflammatory response which causes the pathological changes in the CNS, alternately 
known as the indirect effects of HIV on the CNS (Eugenin, et al., 2006).  This 
inflammatory response activates migration of more microglia to the site where 
cytotoxic responses occur such as: release of reactive oxygen species and nitric 
oxide, and secretion of cytokines (Hegg, et al., 2000), as well as overstimulation by 
neurotransmitters of the N-methyl-D-aspartate type receptor (NMDAR) system 
(Mitchell, 2006).   The release of these proinflammatory mediators damages the 
structure of the surrounding cells which impacts on their functioning, leading to 
neuronal loss as a result of monocyte recruitment (Ivey, et al., 2009).  And so the cycle 
continues by means of a cytotoxic cascade (Pulliam, et al., 1991).  This damage 
creates a variety of CNS abnormalities which are known as HIV encephalopathy. 
 
Pathological changes associated with HIV encephalopathy are: diffuse myelin pallor; 
astrogliosis; disseminated glial-microglial nodules; dendritic destruction and neuronal 
loss; and fusion of microglia resulting in multinucleated giant cells (MGC), the hallmark 
of CNS infection by HIV (Sharer, 1992; Brew, et al., 1988; Navia, et al., 1986a; Navia, 
et al., 1986b; Sharer, et al., 1985).  Neuroimaging shows abnormalities consisting of 
enlargement of the subarachnoid space and ventricles, calcifications of the basal 
ganglia and the frontal lobe white matter (Tardieu, 1998; Belman, et al., 1986), 
cerebral atrophy, white matter lesions (De Carli, et al., 1993), and demyelination 
(Angelini, et al., 2000), which correlate with the microscopic findings. 
 
To conclude, CNS infection by HIV happens early after primary infection and results in 
diffuse damage of neural tissue with devastating clinical manifestations which are the 
effects of HIV encephalopathy.  The neurological impairments are more marked in 
children who have acquired HIV through vertical transmission due to an immature 
nervous system.  The following section will discuss the clinical presentation of HIV 
encephalopathy. 
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2.3.2 Clinical Manifestations of HIV Encephalopathy 
 
HIV encephalopathy as a clinical diagnosis is the umbrella term given to the wide 
spectrum of presentations seen with CNS infection by HIV (Hilburn, et al., 2010; Sherr, 
et al., 2009; Van Rie, et al., 2007; Smith et al., 2006; Brouwers, et al., 1995; Chase, et 
al., 1995; Aylward, et al., 1992; Belman, 1992).  It must be noted that there is a 
distinctly different pattern of clinical presentation seen in children when compared to 
the dementias seen in adults, due to the effect of the virus on an immature CNS 
(Smith, et al., 2006; Belman, 1997; Chase, et al., 1995). 
 
HIV encephalopathy in children is classified as a World Health Organization (WHO) 
Clinical Stage 4 which is an Acquired Immune Deficiency Syndrome (AIDS) defining 
illness.  Currently the World Health Organization (p. 37, 2007) states that clinical 
diagnosis of HIV encephalopathy in children younger than 15 years of age requires 
identification of “at least one of the following progressing over at least two months in 
the absence of another illness: 
failure to attain, or loss of, developmental milestones 
or loss of intellectual ability; 
or, 
progressive impaired brain growth 
demonstrated by stagnation of head circumference; 
or, 
acquired symmetrical motor deficit 
accompanied by two or more of the following: 
paresis, pathological reflexes, ataxia and gait disturbances.” 
 
WHO recommends that definitive diagnosis of HIV encephalopathy can be made 
(when other causes have been excluded) if neuroimaging demonstrates atrophy and 
basal ganglia calcification (WHO, p.37, 2007), which is not feasible for the majority of 
children living in developing countries. 
 
The occurrence of HIV encephalopathy is reported more frequently among children 
presenting with symptomatic disease during the first two years of life (Newell, 1998).  
HIV encephalopathy is likely to present more frequently in this time period as the first 
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years of life are synonymous with rapid myelination as well as the most substantial 
development of the CNS (Willen, 2006; Blanchette, et al., 2001); the virus is infecting 
and thus damaging an immature CNS at a critical time point.  It is also noted that there 
is a higher cumulative incidence of encephalopathy in children compared to adults 
during the first and second years post-infection (Tardieu, et al., 2000).  This is likely to 
occur due to 90% of children being infected with HIV through vertical transmission and 
thus the incidence of HIV encephalopathy coincides with the effects of HIV on an 
immature CNS.  Correlations have been made between low birth weight, smaller head 
circumference and early occurrence of symptomatic CNS disease (Tardieu, et al., 
2000).  Although, these correlations need to be verified according to the time of 
transmission of the infants studied so as to provide explanation for differing clinical 
presentations between in utero infection, infection during labour and delivery or 
infection through breastfeeding. 
 
Neurological dysfunction is often the earliest sign of HIV infection in infants and young 
children (Pizzo, et al., 1988) and can manifest as cognitive, language and/or motor 
delays.  In developing countries where access to HIV management is stringent, 
identification of these signs (and eliminating other causes) aids in the presumptive 
diagnosis of HIV infection (WHO, 2007b) – permitting infants and children to start 
ART.  HIV encephalopathy has a progressive or static course of disease progression 
(Civitello, 2003). 
 
Progressive encephalopathy has two subtypes – subacute progressive or plateau 
(Civitello, 2003).  Subacute progressive encephalopathy has a slow, insidious onset 
and is clinically apparent in infants and young children and is the most severe form of 
the disease.  It presents as the loss of previously acquired, or failure to attain 
milestones and progressive, generalised motor dysfunction (Belman, et al., 1988; 
Epstein, et al., 1988) including oromotor dysfunction.  Plateau encephalopathy is 
characterised by an indolent course of clinical progression where acquisition of 
milestones occurs at a slower rate than previously acquired skills.  Brain growth slows 
as does cognitive development, and spastic diplegia is common (Civitello, 2003).  
Acquired microcephaly is a common finding with progressive encephalopathy. 
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Static encephalopathy is clinically evidenced by a slow rate of development, without 
loss of skills (Civitello, 2003) with poor brain growth and mild atrophy (Belman, et al., 
1988; Epstein, et al., 1988).  Due to the subtle clinical manifestations of this course of 
the disease, children who develop static encephalopathy in developing countries are 
often only diagnosed with HIV encephalopathy at school-age due to this form of the 
disease manifesting as lower cognitive attainment (Mialky, et al., 2004). 
 
Literature reporting on the clinical manifestations of HIV encephalopathy in children 
can be confounded by: inconclusive definitions of HIV encephalopathy where only the 
extreme spectrum of the disease are observed; inclusion of children with opportunistic 
CNS infections or CNS tumours secondary to HIV; inclusion of children who may have 
suffered CNS damage through other factors such as intravenous drug use and/or 
alcohol abuse which is usually seen in studies from the developed world (Blanchette, 
et al., 2001; Chase, et al., 2000; Mellins, et al., 1994; Nozyce, et al., 1994; Ultmann, et 
al., 1985) and/or factors that increase poor early child development (poverty and, poor 
health and nutrition) which are commonly found in studies from the developing world.  
These factors will be considered in section 2.5 when discussing the findings of clinical 
studies. 
 
2.4 Developmental Delay 
 
This section will discuss the delay in cognition, language and motor development 
associated with HIV encephalopathy. 
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2.4.1 Cognitive Delay 
 
Neurocognitive impairment has been shown to result from a direct infection of 
macrophages and microglia in the CNS (McGrath, et al., 2006; Angelini, et al., 2000; 
Safriel, et al., 2000; Mintz, 1999; Brouwers, et al., 1995).  Cognitive delay in HIV-
infected children has been well documented in numerous studies with a variety of 
clinical manifestations.  These include: behavioural impairments, learning 
impairments, lower intellectual function, poor ability in sequential processing, attention-
deficit disorders; and spatial memory impairment (Ruel, et al., 2012; Grover, et al., 
2007; Willen, 2006; Chase, et al., 2000; Blanchette, et al., 2001; Pearson, et al., 2000; 
Boivin, et al., 1995; Gay, et al., 1995; Brouwers, et al., 1995; Mellins, et al., 1994; 
Nozyce, et al., 1994). 
 
2.4.2 Language Delay 
 
Language is a complex skill which is dependent on both cognitive and motor function 
(Wolters, et al. 1997).  Studies have identified that expressive language is more 
severely affected than receptive language in HIV-infected children (Van Rie, et al., 
2008; Wolters, et al., 1997).  Common problems observed in children with HIV 
infection are: feeding problems and impaired articulation (Wolters, et al., 1997).  
 
2.4.3 Motor Delay 
 
Motor delay in HIV-infected children is apparent in the early postnatal period (Chase, 
et al., 1995; Nozyce, et al., 1994).  Due to motor development being synonymous with 
obvious child developmental milestones (such as head control, sitting, crawling and 
walking), motor delay can assist in a presumptive diagnosis of HIV infection during this 
period (Hilburn, et al., 2010).  Motor impairments consist of: abnormal muscle tone, 
muscle weakness, poor coordination and hyperreflexia (Drotar, et al., 1997; Chase, et 
al, 1995; Msellati, et al., 1993). 
 
Table 2.1 shows a summary of clinical studies that have described the extent of 
cognitive, language and motor delay in HIV-infected children in sub-Saharan Africa.  A 
list of the abbreviations used in the table will follow the table. 
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Table 2.1 Studies showing extent of developmental delay in HIV-infected children 
 
Author Year Country Population 
Size 
Age of 
Children 
Percentage of 
HIV-infected 
children with 
delay 
Msellati, et 
al. 
1993 Rwanda 50+ 
136- 
32u 
6-24 mo 31% (12 mo of age) 
40% (18 mo of age) 
Boivin, et al. 1995 DRC 14+ 
20- 
16c 
<24 mo All infected infants 
had social and 
motor deficits 
Drotar, et al. 1997 Uganda 59+ 
211- 
107c 
0-24 mo At 12 mo of age: 
26% cognitive 
30% motor 
McGrath, et 
al. 
2006 Tanzania 327 6-18 mo 26% general delay 
Bagenda, et 
al. 
2006 Uganda 28+ 
37- 
42e 
6-12 yrs No significant delay 
or neurological 
impairment 
Baillieu and 
Potterton 
2008 South Africa 40+ 18-30 mo 70% cognitive 
82.5% language 
85% gross motor 
12.5% fine motor 
Smith, et al. 2008 South Africa 39+ Mean 60 
mo 
33.3% motor 
dysfunction 
33-81% subnormal 
intelligence 
quotients 
Van Rie, et 
al. 
2008 DRC 35+ 
35a 
90c 
18-72 mo 60% cognitive 
29% motor 
85% expressive 
language 
77% receptive 
language 
Potterton, et 
al. 
2009b South Africa 60+ 
62- 
<48 mo 52% cognitive 
72% motor 
Shead, et al. 2010 South Africa 16+ 
24- 
16-42 mo Significant mental 
and motor delay 
Jelsma, et al. 2011 South Africa 21+ 
23- 
Mean 
52.8 mo 
All 21 children who 
were HIV infected 
were significantly 
delayed. 
Lowick, et al. 2012 South Africa 30+ 
30c 
55-75 mo 90% severely 
delayed 
46.7% mental 
handicap 
Ruel, et al. 2012 Uganda 93+ 
106- 
2-12 yrs Significant 
neurocognitive and 
motor deficits 
compared to 
controls 
 
  
 
 
29 
 
Abbreviations used in Table 2.1 
 
+ HIV-positive (HIV+) 
- HIV-negative (HIV-) 
a HIV-infected, affected 
e  HIV-exposed, uninfected (HEU) 
mo months 
yrs years 
 
 
2.5 Clinical Studies 
 
This section will review the clinical studies on paediatric HIV-related neurological 
impairment from the early 1980s to present day.  Clinical studies from developed 
countries will be discussed first as these were the first to emerge.  A discussion will 
also be presented on the effect of ART on the development of children infected with 
HIV.  Finally, studies from sub-Saharan Africa will be reviewed as these relate to this 
study and present challenges different from those in the developed world. 
 
2.5.1 Developed World 
 
Pre-antiretroviral Era 
In June, 1981 the United States (US) Centers for Disease Control and Prevention 
(CDC) issued the first official report on AIDS which discussed five cases of a rare 
pneumonia (Pneumocystis carinii pneumonia) presenting in homosexual men in Los 
Angeles, California (MMWR Weekly, 1981). Reports from medical communities in New 
York and California had also been made earlier that year on an aggressive form of 
Karposi’s sarcoma presenting in eight young homosexual men in New York (Hymes, 
et al., 1981).    These diseases were later evidenced as AIDS-related.  It was a 
common assumption at this time that AIDS was a homosexual male’s disease 
(Altman, 1981).  HIV was however unknown as the pathogen implicated until 1985 
(Marx, 1985) and only named as HIV in 1986 (Coffin, et al., 1986) but the link between 
HIV and AIDS was still not clear.  Altman (1981) reported on Dr Curran of the CDC as 
saying “the best evidence against contagion is that no cases have been reported to 
date outside the homosexual community or in women.”  Inevitably, in August 1982, a 
20-month old male infant from California, who received multiple blood transfusions 
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after a complicated birth history, died of AIDS (MMWR Weekly, 1982).  This was the 
first official report on paediatric HIV in the US. 
 
Given the above history on the emergence of HIV/AIDS, it is not surprising that the 
first clinical studies to emerge in 1985 that focused on paediatric HIV-related 
neurological impairments had their limitations.  Methodological issues included: case 
study design; small sample sizes (a range of four to 16 children); wide age ranges (six 
months to 11 years); no comparison of cases with controls; diagnoses of AIDS was 
made from clinical symptoms and signs of defective cell-mediated immunity which 
ensured an inclusion of children with symptomatic HIV infection (AIDS-related 
complex, or AIDS); poorly standardised neurodevelopmental assessment; and 
inclusion of confounding factors for child development such as drug-exposure during 
pregnancy, premature gestation, small-for-gestational age birth weights, CNS 
infections (by cytomegalovirus, Epstein-Barr virus, Haemophilus influenzae meningitis, 
and Toxoplasmosis gondii), co-infection with Pneumocystis carinii pneumonia, history 
of seizures, orphan hood, and, other medical conditions affecting growth and 
development (Belman, et al., 1985; Epstein, et al., 1985; Ultmann, et al.,1985).   
 
Although not methodologically sound, these studies offered much-needed information, 
as well as public awareness of a deadly virus at a time when very few public health 
initiatives were being undertaken to research and publicise the disease (Shilts, 1987).  
The clinical studies in the 1980s were also the first to document the neurological 
sequelae seen in children with HIV infection, identify a correlation between clinical 
disease progression with pathological findings (Belman, et al., 1988; Belman, et al., 
1985; Epstein, et al., 1985; Ultmann, et al., 1985) and suggest HIV infection as the 
primary cause of encephalopathy (Epstein, et al., 1986).  Attempts were made during 
this time to objectify the medical observations by employing the first edition of the 
BSID, the Denver Developmental Screening Test, First Edition and the Stanford Binet 
(Belman, et al., 1985; Ultmann, et al., 1985).  Epstein and colleagues (1985) relied on 
CT scans and neurological examinations.  Belman and colleagues (1988) employed a 
longitudinal study design and included 68 HIV-positive children from six weeks to 13 
years of age.  In this study, Belman, et al. found evidence of CNS dysfunction in 90% 
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of the population.  However, this high prevalence was documented in an age when 
referral was dependent on clinical signs of AIDS and thus implicates those children 
with already established severe progression of the disease.  The primary aim of this 
study, as was the aim of the previous studies in the 1980s, was to document clinical 
signs and symptoms, and disease progression, and not the prevalence of HIV-related 
neurological dysfunction.  The study by Belman, et al. (1988) and the review by 
Epstein, et al. (1988) identified categories of HIV encephalopathy, namely progressive 
and static.  This is interesting as it shows that the authors were sensitised to the 
variations in disease progression and gave pointers for future research as to 
pathogenic mechanisms of vertical transmission, timing of infection, and suggested 
that the most useful approach to paediatric HIV infection is one of prevention. 
  
Some of the hallmark features which the World Health Organization (WHO, 2007b) 
has adopted to aid in the clinical diagnosis of HIV encephalopathy in children were 
documented through observation during this period: acquired microcephaly, pyramidal 
tract signs and encephalopathies (Belman, et al., 1988). 
 
Clinical studies started to emerge in the 1990s from Europe and Africa with continued 
studies from North America.  The focus in developed countries shifted from 
descriptions of the effect of HIV on the CNS to documenting the extent of neurological 
and developmental impairment (Belman, et al., 1996; Gay, et al., 1995; Lobato, et al., 
1995; and European Collaborative Study, 1990).  Improvements in methodology to 
support this aim included: longitudinal design; smaller age ranges from birth to four 
years with increased sample sizes (Belman, et al., 1996; Pollack, et al., 1996; Chase, 
et al., 1995; Gay, et al., 1995; Mellins, et al., 1994; Nozyce, Hittelman, et al., 1994; 
Condini, et al., 1991; and, European Collaborative Study, 1990); employing the use of 
the BSID-I, a standardised assessment tool (Belman, et al., 1996; Pollack, et al., 1996; 
Chase, et al., 1995; Gay, et al., 1995; Mellins, et al., 1994; and, Nozyce, Hittelman, et 
al., 1994); introduction of control groups (Belman, et al., 1996; Pollack, et al., 1996; 
Chase, et al., 1995; Gay, et al., 1995; Mellins, et al., 1994; Nozyce, Hittelman, et al., 
1994; Condini, et al., 1991; European Collaborative Study, 1990; and Diamond, et al., 
1990); and minimising confounding factors (Belman, et al., 1996). 
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However, limitations were present and included: failure to state how HIV diagnosis 
was made (Lobato, et al., 1995); lack of uniformity in diagnostic procedures (European 
Collaborative Study, 1990) due to the available diagnostic tests at the time having 
poor sensitivity and specificity for the age-range studied; blinding to the HIV-status of 
the child was redundant as clinical signs of HIV infection were used to diagnose the 
children in some of these studies, and therefore would be obvious to the assessor 
(Belman, et al., 1996; Nozyce, Hittelman, et al., 1994; European Collaborative Study, 
1990; and Diamond, et al., 1990); and, some studies failed to objectify their findings by 
employing the use of a standardised assessment tool (Lobato, et al., 1995; Blanche, 
et al., 1990; European Collaborative Study, 1990).  Despite using neurological 
examination exclusively, Blanche and colleagues (1990), and the European 
Collaborative Study (1990) were in agreement with their findings that approximately a 
third of children with HIV showed higher risks of suffering HIV-related neurological 
impairment, and this concurs with a study conducted by Belman, et al. (1996) which 
used neurological examination in conjunction with the BSID-I and found that 25% of 
children infected with HIV had neurological impairment.  It is also important to note 
that the discrepancies observed in quantifying the extent of neurological and 
developmental impairment between studies conducted in the 1980s and the 1990s 
exist due to differences in the: aims of the research conducted; and methodology 
employed, namely study design (case studies versus longitudinal prospective studies) 
and sample size.  It must also be stated that in the early 1990s, as in the 1980s, these 
studies were limited by the inconclusive knowledge of HIV available. 
 
Some important findings on paediatric HIV-related neurological and developmental 
impairments emerged at this time.  Children with symptomatic HIV infection are more 
at risk of developmental impairment than asymptomatic HIV-infected children (Nozyce, 
et al., 1994) indicating that disease progression is correlated with increased morbidity 
and mortality (Belman, et al., 1996; Lobato, et al., 1995).  A diagnosis of HIV-
encephalopathy indicates a mean survival time of 22 months with natural progression 
of the disease, where the highest risk of HIV-encephalopathy (4%) occurs in the first 
year of life (Lobato, et al., 1995).  The mean rate of development in the first 24 months 
of life is slower in HIV-infected children than in HIV-exposed uninfected children 
(Chase, et al., 1995; Gay, et al., 1995).  Belman, et al. (1996) also established that 
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HIV-exposed uninfected infants’ neurological development is not different from that of 
HIV-uninfected controls. 
 
Antiretroviral Era 
In the decade following the 1990s, studies started to be published in the United States 
and Puerto Rico using data from the Woman and Infants Transmission Study (WITS) 
(Nozyce, et al., 2006; Smith, et al., 2006; Llorente, et al., 2003; Macmillan, et al., 2003; 
Chase, et al., 2000; Smith, et al., 2000), the Pediatric AIDS Clinical Trials Group 
(Lindsey, et al., 2007; Pearson, et al., 2000), and from the Adolescent Master Protocol 
(Rice, et al., 2012).  These studies were primarily concerned with describing the type 
of neurodevelopmental impairment.  One study looked at the risk of 
neurodevelopmental impairment associated with timing of HIV infection (Smith, et al., 
2000).  Common themes that were found in these studies were that HIV infection 
increases the risk for neurodevelopmental impairment, namely cognitive and motor 
domains (Blanchette, et al., 2001; Macmillan, et al., 2001; Chase, et al., 2000; Smith, 
et al., 2000), and behavioural and cognitive domains reported by Nozyce et al (2006).  
Other studies reported on severity of impairments being associated with outcomes in 
HIV-infected children (Smith, et al., 2006; Llorente, et al., 2003; Pearson, et al., 2000) 
with a reduction in mortality and severity with the use of ART (Lindsey, et al., 2007).  
Foster and colleagues (2006) reported on HIV-positive children in the United Kingdom 
less than three years of age and found persistent neurodevelopmental impairment 
despite ARVs/ART.  Although it is important to note that some of the children included 
in this retrospective case note review were treated in the pre-ART era, while others 
received ART (Foster, et al., 2006). 
 
A recent study has identified the need to report on language impairment in HIV-
positive children and found no significant effect of HIV infection status on the odds of 
language impairment (Rice, et al., 2012).  This is contrary to a cross-sectional study 
conducted by Koekkoek et al (2008) in the Netherlands where HIV-infected children in 
a similar age-range showed poorer verbal fluency than age-norms.  The study by Rice 
et al (2012) was of cross-sectional design, which meant that language function was 
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assessed at one time-point, and the groups were not well-matched (the HIV-exposed 
group was younger and living in lower income households) – two factors that are 
known to introduce bias when interpreting the results. 
 
The methodology employed in these studies suggests improved accuracy in the 
validity of the results obtained.  These factors include: longitudinal design (except for 
those studies by: Rice, et al., 2012; Koekkoek, et al., 2008; Foster, et al., 2006; and, 
Blanchette, et al., 2001), larger sample sizes as a result of access to multiple research 
sites, use of valid and reliable outcome measures in addition to brain scanning and 
neurological assessment, and more structured inclusion and exclusion criteria.   
 
All except one study (Chase, et al., 2000) showed that children with HIV infection 
received ARVs according to accepted guidelines (at the time of data collection) on the 
standard of care for paediatric HIV patients (Rice, et al., 2012; Koekkoek, et al., 2008; 
Lindsey, et al., 2007; Foster, et al., 2006; Nozyce, et al., 2006; Smith, et al., 2006; 
Llorente, et al., 2003; Macmillan, et al., 2003; Blanchette, et al., 2001; Pearson, et al., 
2000; Smith, et al., 2000).  The advancements in pharmacological management during 
the data collection period of these studies introduced error which could not be 
controlled.  Three options of ARV regimens were generally available during the time 
periods of data collection for these trials.  Therefore, depending on the year that the 
child was assessed dissimilarities between HIV-positive children will exist because of 
how the virus impacts on development in the presence of differing efficacy of these 
pharmacological interventions.  The most obvious example of this effect is the study 
conducted by Lindsey et al (2007).  
 
A summary of the clinical studies from the developed world that have been discussed 
in this section can be viewed in Table 2.2 on the next page.  Abbreviations used in this 
table will follow for ease of reference. 
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Table 2.2 Clinical studies from the developed world 
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2.5.2 Effect of ART on the Development of HIV-Infected Children 
 
The first antiretroviral, AZT, was available within the first decade of the discovery of 
HIV (De Clercq, 2009).  Numerous regimens including AZT monotherapy became 
available in the decade following 1987: use of two NRTIs, or NNRTIs without PIs 
(multi-ART); and the combined use of three or more ARVs with one or more highly-
active compound (ART).   
 
Of all these regimens, timely intervention with ART is the most effective strategy 
employed to date to improve the prognosis for children infected with HIV, and 
decrease mortality (Llorente, et al., 2003; van Rossum, et al., 2002).  Significant 
improvements in child nutritional and growth status have been made with the use of 
ART (Jaspan, et al., 2008; Eley, et al., 2006; Verweel, et al., 2002).  Positive, but 
limited improvements in neurodevelopmental functioning have been reported in 
numerous studies, however, these improvements did not reverse the existing 
neurodevelopmental impairment (Lindsey, et al., 2007; Foster, et al., 2006; Coplan, et 
al., 1998; Raskino, et al., 1999; Pizzo, et al., 1988).  Despite ART, 
neurodevelopmental impairments persist due to existing regions of the CNS having 
sustained injury at critical periods of brain development (Foster, et al., 2006; Willen, 
2006), as well as the blood-brain barrier (BBB) effectively preventing adequate 
permeation of ART into the CNS to suppress viral replication (Letendre, et al., 2008; 
Miller, 2002).  Letendre et al (2008) found that the only ARVs effective in permeating 
the BBB are: NVP, AZT and Abacavir.  In the management of infants, utilising CNS-
penetrating regimens are not always possible.  Single-dose NVP (sd-NVP) is widely 
used in sub-Saharan Africa in the prophylactic treatment of infants in the management 
of PMTCT; however there is controversy over its use due to the emergence of NNRTI 
resistance mutations developing readily (Arrivé, et al., 2007; Kassaye, et al., 2007).  
One study reports the prevalence of NVP resistance in children following single-dose 
administration as 52.6% (Arrivé, et al., 2007).  However other studies report that this 
resistance disappears after time (Kassaye, et al., 2007). 
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It is therefore indicated that universal access to PMTCT services is the only way to 
prevent HIV-related neurodevelopmental impairment by preventing transmission of 
HIV altogether.  For those children who are already infected, early intervention with 
ART is indicated so as to minimise the detrimental effects of HIV on the developing 
CNS.  
 
2.5.3 Developing World 
 
A number of studies have been conducted in Africa.  However, too few in proportion to 
the 90% of children affected by HIV who are living in sub-Saharan Africa  (UNAIDS, 
2010) where poorly resourced and inaccessible health systems have contributed 
significantly to the spread of HIV (ter Kuile, et al., 2004).  A possible explanation for 
the few studies is mainly due to high rates of mortality associated with perinatal HIV 
infection where approximately 50% of these children died within the first two years of 
life (Newell, et al., 2004).   ART was only available in Zimbabwe in 2004, and even 
then, paediatric formulations were still not available until the end of 2005 (UNGASS, 
2009).  With ART becoming increasingly available, sub-Saharan Africa now faces the 
same concerns that the developing world faced two decades ago.  How can these 
under-resourced countries accommodate HIV-associated disability (Abubakar, et al., 
2008)? 
 
Some of the first studies to be published were conducted in Uganda, the Democratic 
Republic of the Congo (DRC) and Rwanda (Drotar, et al., 1997; Boivin, et al., 1995; 
Msellati, et al., 1993).  These studies all employed a longitudinal design, a small age-
range, and utilised outcome measures.  Msellati and colleagues (1993) devised their 
own measure which was based on the Denver Developmental Screening Test (DDST) 
and included only 15 items (three to five gross motor items; two to three fine motor 
items; two to three social contact items; and three language items).  This measure was 
also not validated either.  The limitations of these studies are similar to those seen in 
the same decade in the developed world:  diagnosis in children younger than 15 
months was limited to clinical signs and symptoms of HIV (Msellati, et al., 1993). 
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All these studies found delays in development, where Drotar et al (1997) reported that 
26% of HIV-infected infants showed cognitive delay, and 30% showed motor delays at 
12 months of age; and, Msellati et al (1993) reported neurologic manifestations in 31% 
(12 months of age) and 40% (18 months of age) of children infected with HIV.  These 
findings correlate with clinical studies done in the developed world (Belman, et al., 
1996; Blanche, et al., 1990; European Collaborative Study, 1990).  Boivin et al (1995) 
did not find differences in language development of preschoolers, whereas the 
Rwandan study did (Msellati, et al., 1993).  Again, it is important to bear in mind that 
Msellati et al (1993) only utilised three language items in their modified DDST 
measure, compared with Boivin et al (1995) who used the DDST in entirety. 
 
Contrary to Msellati et al (1993) reporting cognitive delays in their Rwandan infants, 
Bagenda et al (2006) found no significant cognitive or neurological differences 
between HIV-infected and uninfected children in Uganda.  The study by Bagenda and 
colleagues (2006) recruited the same children from the study by Drotar et al (1997) 
who had reached school-age to assess cognitive development (Abubakar, et al., 
2008).  A possible explanation for the discrepancies between these studies is that 
children from the first Ugandan study (Drotar, et al., 1997) did not have access to 
ART.  Therefore this study (Bagenda, et al., 2006) may be confounded by survival bias 
where children with more severe impairments would have died before reaching 
school-age. 
 
A study in Tanzania in the new millennium (McGrath, et al., 2006) was the first to 
explore the effect of timing of MTCT on neurodevelopment.  This study is comparable 
to a study done in the United States by Smith and colleagues (2000) who also used 
the BSID-I.  Both these studies found that early infection presented an increased risk 
of neurodevelopmental impairment.  McGrath et al (2006) found that those infants who 
tested HIV-positive within the first 21 days had a 14.9 times higher rate (relative risk) 
of becoming developmentally delayed in all aspects of mental functioning, and an 
eight-point-seven times higher rate of motor development, when compared with 
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uninfected children.  However the authors (McGrath, et al., 2006) acknowledge that 
their study introduced error as some of the infants could have been infected by breast 
milk in the first 21 days of life, and thus the risk of developmental delay may be 
underestimated.  This study found a general developmental delay of 26% in HIV-
positive children compared to only 12% in the uninfected group (McGrath, et al., 
2006).   
 
Studies in South Africa looked at: describing the neurological and neurocognitive 
deficits in HIV-infected children and the short-term effect of ART (Smith, et al., 2008), 
quantifying the extent of neurodevelopmental delay (Baillieu and Potterton, 2008), 
identifying the neurodevelopmental status of HIV-infected children in Soweto 
(Potterton, et al., 2009b) and subsequently employing an intervention programme to 
address deficits (Potterton, et al., 2009a); as well as studying the effects of HIV on the 
neurodevelopment of institutionalised children (Jelsma, et al., 2011; Shead, et al, 
2010). 
 
With increasing use of ART in paediatric populations in sub-Saharan Africa, 
researchers have identified the need to continue to research the effects of HIV on 
neurodevelopment in populations which are increasing in prevalence, for example 
preschoolers (Lowick, et al., 2012; Van Rie, et al., 2008).  Lowick et al (2012) found 
that 90% of the HIV-infected children in Soweto, South Africa, exhibited general 
developmental delay despite ART.  However a high number of children (76.7%) in the 
comparison group also demonstrated delay.  A possible confounding variable was that 
the authors were unable to determine the status of the apparently healthy comparison 
group, as well as being unable to control for other risk factors of early child 
development (see section 2.6).  Van Rie et al (2008) found that 60% of HIV-infected 
children in the DRC showed severe cognitive delay, 28.6% showed severe motor 
delay, and 84.6% and 76.7% of HIV-infected children showed delay in language 
expression, and comprehension, respectively.  Comparisons cannot be made between 
these studies as they both employed different assessments of child development.  
Given the limitations of these studies, it is apparent that children with HIV are 
significantly more affected than their uninfected peers.  More studies are needed to 
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explore the effects of intervention on improving neurodevelopment in these children 
because as ART becomes more accessible, children will be facing reduced quality of 
life with extended life through ART.  Potterton et al (2009a) found a positive effect of a 
basic home stimulation programme on the neurodevelopmental status of young 
children infected with HIV.  
 
A recent study conducted in Zimbabwe (Kandawasvika, et al., 2011) found that the 
risk of neurodevelopmental impairment among HIV-exposed infected infants was 
double that among their non-infected peers (OR 2.1) when using the Bayley Infant 
Neurodevelopmental Screener (BINS).  Kandawasvika and her colleagues also 
reported that the prevalence of neurodevelopmental impairment in all children 
assessed was nine-point-four percent.  They also confirmed that head circumference 
was associated with an OR 2.22 risk of neurodevelopmental impairment when 
controlling for other factors; head circumference is a simple assessment that can be 
employed in practice to identify children at risk of neurodevelopmental impairment.  
 
All studies which measured motor development (Lowick, et al., 2012; Ruel, et al., 
2012; Jelsma, et al., 2011; Shead, et al., 2010; Potterton, et al., 2009b; Baillieu and 
Potterton, 2008; Smith, et al., 2008; Van Rie, et al., 2008; McGrath, et al., 2006; 
Drotar, et al., 1997; Boivin, et al., 1995; Msellati, et al., 1993) and most of the studies 
that assessed language development (Lowick, et al., 2012; Baillieu and Potterton, 
2008; Smith, et al., 2008; Van Rie, et al., 2008; Msellati, et al., 1993) reported 
significant differences between the HIV-infected children and the uninfected children.   
 
Sub-Saharan Africa has far greater challenges (poverty, malnutrition and poor 
healthcare) than more developed countries – these challenges greatly impact on the 
ability to examine children infected with HIV.  However, it is clear from the studies 
presented that children living with HIV in developing countries are still at risk of HIV-
related neurodevelopmental impairments despite the introduction of ART (Van Rie, et 
al., 2008) especially with early HIV infection (McGrath, et al., 2006) and with severity 
of disease stage (Ruel, et al., 2012).  A summary of these studies can be seen in 
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Table 2.3 on the next page.  Abbreviations used in this table will follow for ease of 
reference. 
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Table 2.3 Clinical studies from the developing world 
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2.6 Risk Factors for Early Child Development (ECD) 
 
ECD is defined as the period below the age of eight years including the prenatal 
period (UN CRC, 2005).  However, most of the available research on ECD shows data 
collected for children younger than five years.  In these critical years a number of 
factors can contribute to the healthy development of children (protective factors), or 
place them at risk (risk factors) (Walker, et al., 2011).  The CNS is also developing 
rapidly in this timeframe, and is itself a bidirectional entity that influences, and is 
influenced by, the environment (Mustard, 2006).  Exposure to developmental risk 
factors can permanently alter the structure and function of the brain (Walker, et al., 
2011).  Facets of a child’s development that can be affected are: sensory-motor, 
cognitive-language and social-emotional (Baker-Henningham and Boo, 2010).  As 
these facets are synonymous with CNS development, they contribute to the foundation 
for: basic learning, school success, economic participation, social citizenry and health 
(WHO, 2007a). 
 
In 2007 it was estimated that 200 million children under five years of age were not 
fulfilling their developmental potential (Walker, et al., 2007b).  The main causes of 
adverse development are: poverty, poor health and nutrition, and deficient care 
(Grantham-McGregor, et al., 2007).  Children who are exposed to these causes are at 
risk of not reaching their developmental potential (Engle, et al., 2011).  Walker and 
colleagues (2007b) identify many risks namely, biological, psychosocial and 
socioeconomic factors which are associated with the causes.  These risk factors can 
co-occur and this has a cumulative effect on the facets of ECD, as the facets are 
interdependent.  The risk factors with the highest prevalence and strongest evidence 
base are: stunting (linear growth retardation), iodine and iron deficiencies, and 
inadequate cognitive and social-emotional stimulation (Walker, et al., 2007b).  In 
addition to these, less documented risks are: maternal depression, intrauterine growth 
restriction and infectious diseases, such as malaria and HIV (Walker, et al., 2007b). 
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Identification of the causes and risk factors is important as it will facilitate identification 
of those children at risk.  Interventions can then be implemented early to ensure that 
risks are prevented or minimised and protective factors are promoted.  Often the 
intervention is the inverse of the risk factor.  However, knowledge not only of these risk 
factors but also of the critical time-points for intervention is important to minimise the 
detrimental effects for ECD (Engle, et al., 2011).  The major economic gains in 
productivity on a national level that can be made from investment in interventions 
promoting ECD are vast.  However, in spite of this, few developing countries have 
made significant steps to positively affect ECD which perpetuates intergenerational 
transmission of poverty, poor health and nutrition, and deficient care for children most 
in need (Grantham-McGregor, et al., 2007). 
 
This paper will discuss the interplay of: poverty; poor health and nutrition, and deficient 
care; and the associated risk factors, in relation to ECD.  For the purpose of clarity, the 
factors will be discussed individually despite many co-occurring. 
 
2.6.1 Poverty 
 
Children living in poverty have increased exposure to biological and psychosocial risk 
factors for ECD, namely poor health and nutrition, and deficient care.  Availability of 
food, poor living conditions, poor health, limited access to education (maternal and 
child education), maternal depression, poor parenting, and many other risks are 
enhanced by poverty and fuel the poverty cycle for the next generation (Walker, et al., 
2011).  Therefore, the developmental consequences of poverty can result in all facets 
of a child’s development being affected.  For example, a social problem caused by 
poverty, such as low maternal education, and maternal depression, can lead to 
inadequate stimulation and poor understanding of nutrition which in turn could lead to 
a child being exposed to inadequate learning opportunities (and thus decreased 
earning capacity in adulthood) and malnutrition (Walker, et al, 2011). 
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Deficient Care 
The primary caregiver is fundamental in the care of the child.  It is their interaction with 
the child that will facilitate or hinder ECD.  It is obvious that many risk factors will 
impact on this relationship (Baker-Henningham and Boo, 2010).  Inadequate cognitive 
and social-emotional stimulation is mainly a consequence of poor quality child-
caregiver interactions and lack of access to services (Engle, et al., 2007).  Factors that 
will increase the likelihood of cognitive and social-emotional deficits which are 
resultant of deficient care are: maternal depression, low maternal education, access to 
learning and institutionalisation (Walker, et al., 2011). 
 
2.6.2 Nutrition 
 
The relationship between nutrition and health is positively correlated and 
interdependent.  This section will discuss the impact of maternal nutrition and health 
on foetal development, as well as childhood nutrition (including breastfeeding) and its 
effects on ECD.  It is also important to understand that poverty will significantly impact 
on nutrition, as well as health, at all stages of foetal and childhood development. 
 
Intrauterine Growth Restriction 
Nutrition can significantly affect all aspects of a child’s development, particularly, 
cognition and motor development.    Maternal nutrition before conception and during 
pregnancy plays a vital role in the growth of the placenta and the foetus (King, 2003; 
Barker and Clark, 1997).  The effects of maternal nutritional deficiencies together with 
maternal infections during pregnancy can cause intrauterine growth restriction (IUGR) 
(Walker et al, 2011).  There is also evidence that suggests that nutrition has the most 
significant role in the intrauterine environment (Barker and Clark, 1997).  This 
environment is more important than genetics of the foetus in the aetiology of chronic 
diseases in later life (Wu, et al., 2004) such as Type 2 Diabetes (Godfrey and Barker, 
2000) and Coronary Heart Disease (Osmond, et al., 1993). 
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Most births are low birth weight (LBW) as a result of IUGR (Walker, et al., 2011).  
Studies that have looked at LBW infants (<2500g) up to the age of three years, show 
deficits in: problem-solving abilities, behaviour and cognitive and motor development 
(Walker, et al., 2004; Gardner, et al., 2003;  Lui, et al., 2001; Grantham-McGregor, et 
al., 1998; Gorman and Pollitt, 1992; Villar, et al., 1984).  One study reported that food 
supplementation for pregnant mothers in their third trimester and for infants up to six 
months of age did not benefit growth of children with LBW (Waber, et al., 1981).   This 
supports that foetal and infant growth and development is dependent on maternal 
nutrition (Wu, et al., 2004), whereby growth is most susceptible to deficiencies of 
nutrients (protein and micronutrients) during implantation (day five to ten post-
fertilisation) and the period of rapid placental development (first trimester of gestation) 
(Waterland and Jirtle, 2004). 
 
Breastfeeding 
Exclusive breastfeeding leads to improvements in school grades by 18 years of age 
and is linked to a ten to 15% difference in income (Victora, et al., 2005).  
WHO/UNICEF recommends exclusive breastfeeding for the first six months of life, and 
thereafter breastfeeding with nutritionally adequate complementary feeding up until 
two years of age (WHO/UNICEF, 2003).  The effect of breastfeeding enhances 
cognitive development, as well as child-mother bonding, and is a known to be a 
protective factor for ECD (Walker, et al., 2011).  Although exclusive breastfeeding is 
practiced in most developing countries in more than a third of infants below six months 
of age, it is the duration that is most important in enhancing ECD, as early 
supplementary bottle-feeding is known to be associated with poorer motor and 
cognitive function (Clark, et al., 2006). 
 
Stunting 
Chronic malnutrition predisposes a child to stunting (linear growth retardation) and can 
begin in utero (WHO, 2007a).  Stunting affects 34% of children younger than five 
years in developing countries (Walker, et al., 2011).  Evidence suggests that stunting 
is predictive of poor psychological functioning, low level school-attainment and 
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decreased likelihood of formal employment by 20-22 years of age (Carba, et al., 2009; 
Walker, et al., 2007a; Alderman, et al., 2006).  Inequalities in development caused by 
stunting are shown to be dramatically improved if interventions are enacted within the 
first two years of life (Crookston, et al., 2010) and include cognitive and social-
emotional stimulation (Winick, et al., 1975). 
 
Micronutrient Deficiencies 
Micronutrients are vitamins or minerals that are essential in minute amounts for normal 
growth and development of organs.  Two micronutrients – iodine and iron, are 
significantly important in ECD because of their effect on CNS development (Walker, et 
al., 2007b).  Iron-deficiency anaemia affects cognition, motor and social-emotional 
development.  Alternately, deficiencies during pregnancy only affect the infant’s 
cognitive and emotional development (Walker, et al., 2007b).  Iodine has a significant 
effect on cognition and behaviour, where in severe cases it causes irreversible mental 
retardation (Walker, et al., 2007b). 
 
Supplementation and fortification of staple foods, with iron has had limited effects on 
reducing these adverse effects when iron deficiency is severe or chronic.  However 
timely supplementation or fortification, before iron deficiency is apparent, is likely to be 
more effective, and this includes supplementation during pregnancy (Engle, et al., 
2007).  Worldwide interventions have been undertaken to reduce iodine deficiencies 
and directly reduce mental retardation by salt iodisation (UNICEF, 2004).  Timing of 
iodine supplementation has been shown to be most effective in the first and second 
trimesters of pregnancy (Qian, et al., 2005). 
 
2.6.3 Health 
 
Poor health has significant implications on ECD.  During pregnancy, maternal 
infections can affect the development of foetal immune systems independently of the 
vertical transmission of pathogens (Dauby, et al., 2012). 
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Infections 
Infections, such as malaria, affect the placenta and contribute to placental insufficiency 
leading to LBW, prematurity and intrauterine growth restriction (Desai, et al., 2007).  
LBW and IUGR are factors which can affect ECD, as discussed earlier.  It has also 
been shown that infants exposed to placental malaria in utero are more susceptible to 
acquiring HIV through mother-to-child transmission (Steiner, et al., 2010).  Infants born 
to mothers with placental malaria also had an increased risk of acquiring malaria 
postnatally (Dauby, et al., 2012), which can cause neurological and cognitive 
impairments (Walker, et al., 2007b). 
 
Paediatric HIV infection has significant implications on ECD because the virus is 
known to be both neurotropic and neurotoxic (Mitchell, 2006; Albright, et al., 2003; 
Tardieu, 1998; Schmitt, et al., 1991).  Infants who are infected through vertical 
transmission are noted to have cognitive, language and motor impairments (Abubakar, 
et al., 2009; Potterton, et al., 2009; Baillieu and Potterton, 2008; Van Rie,  et al., 2008; 
Lindsey, et al., 2007; Foster, et al., 2006; Blanchette, et al., 2001; Drotar, et al., 1997; 
Belman, et al., 1996; Pollack, et al., 1996).  HIV infection is associated with stunting 
and wasting (weight-for-length) in the first three months of life (Venkatesh, et al., 
2010).  In addition to the effects of HIV on health, there is evidence that shows that 
children who are not themselves infected with HIV are exposed to psychosocial risk 
factors for ECD, where they are missing developmental opportunities because they 
are having to care for a parent, or are themselves the head of a household due to 
orphan hood (ANNECA, 2006). 
 
Increasing evidence is showing the importance of identifying risks for ECD, not only 
because of the effects on a child’s developmental potential, but also because it can 
lead to public health issues and poor economic growth. 
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Many risk factors for ECD are caused by poverty, poor nutrition and health and 
deficient care.  IUGR, stunting, micronutrient deficiencies, infections and inadequate 
cognitive and social-emotional stimulation have been discussed because these are 
the risk factors which are found to have the most significant outcome on ECD.  
Identification of these risk factors, as well as knowledge on the critical time-points will 
lead to timely intervention and thus promote ECD. 
 
2.7 Conclusion 
 
This chapter has reviewed the literature and provided a background to: the 
epidemiology of HIV; treatment and management of paediatric HIV; the developing 
CNS and HIV infection; clinical studies of paediatric HIV from the developed and 
developing worlds; and risk factors for ECD.  It is hoped that this background provides 
rationale for the present study.  
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CHAPTER 3: METHODS 
 
This chapter will discuss the research setting, ethical considerations, study design, 
subjects, materials and measurements, the procedures used to collect data and data 
analysis. 
 
3.1 Research Setting 
 
This study was conducted at Newlands Clinic and Parirenyatwa Opportunistic 
Infections (OI) Clinic in Harare, Zimbabwe.  These clinics provide outpatient care and 
treatment to adults and children living with HIV/AIDS. 
 
Newlands Clinic is a family-centred, nurse-led clinic that operates in a Private-Public 
Partnership.  In addition to the medical care provided by doctors and nurses (trained in 
counselling), ancillary services such as Dentistry, Physiotherapy and Woman’s Health 
services are provided free of charge.  There is also an onsite laboratory and 
pharmacy. 
 
Parirenyatwa OI Clinic is a public institution where adults and children attend 
appointments with doctors, nurses and trained counsellors.  There is an onsite 
pharmacy.  As there is no onsite laboratory, this site shares the facilities of the 
Parirenyatwa Hospital which is located on the same premises, or sends samples to 
the National Reference Laboratory.  Ancillary services can also be accessed in the 
main hospital. 
 
3.2 Ethical Considerations 
 
Ethical Clearance was obtained from the Ethics Committee of the University of the 
Witwatersrand (Appendix I).  In addition to this, approval was obtained from the 
Medical Research Council of Zimbabwe (Appendix I) to conduct the study at Newlands 
Clinic and Parirenyatwa OI Clinic. 
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Informed consent was obtained from the mothers prior to assessment where each 
mother signed a consent form.  Data of the participants was anonymised by assigning 
a study number, which was recorded on all documentation so that identification could 
not be made from revealing demographic data (name, date of birth and address).  
Mothers were given the opportunity to opt-out at any stage if they no longer wanted to 
participate in the study without any prejudice to their continued care at the clinic where 
they received medical care 
 
3.3 Study Design 
 
This was a cross-sectional study of HIV-exposed infants from six weeks to 12 months 
of age.  HIV-positive mothers with infants who met the inclusion criteria were invited to 
participate if their infants were accessing Newlands Clinic or Parirenyatwa OI Clinic 
and were tested using DNA-PCR.  All patients attending these clinics are black African 
infants, from similar socioeconomic and cultural backgrounds and are representative 
of an urban, black Zimbabwean population. 
 
3.4 Subjects 
 
HIV-positive mothers with infants between six weeks to 12 months of age attending 
Newlands Clinic or Parirenyatwa OI Clinic who were tested (DNA-PCR) for HIV, were 
invited to participate.  The study consisted of 60 (28 HEI; 32 HEU) infants.  Infants 
were excluded from the study if: their mother was not present for the assessment; they 
tested negative more than six weeks before assessment and were still being 
breastfed; they were premature (less than 37 weeks gestation); they suffered any CNS 
infections; they had apparent congenital deformities; or if they were receiving 
physiotherapy. 
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3.5 Materials and Measurements 
 
3.5.1 Immunology and Virology 
 
Where available, CD4 counts and percentages, viral loads and clinical staging of HIV 
were recorded on the Data Collection Sheet (Appendix IV) for both mothers and 
infants enrolled in this study.  Diagnosis of HIV infection in infants was made using 
DNA-PCR testing available at both clinics. 
 
3.5.2 Anthropometric Measurements 
 
Vertex-to-heel recumbent length was measured with the infant supine – boards were 
placed at the top of the head and at the feet (knees and hips straight) and the distance 
was measured in centimetres using a tape measure.  The measurements were 
rounded to the nearest zero-point-one centimetre.  Weight was measured with the 
infant naked on a calibrated, electronic digital scale.  Head circumference was 
recorded with a tape measure placed over the eyebrows, above the tops of the ears 
and to the occiput.  All measurements were taken by the principal investigator. 
 
3.5.3 Bayley Scales of Infant and Toddler Development (Third Edition) 
 
The BSID-III was used to assess development of the infants in this study.  The BSID-
III is a revision of the second edition of the BSID which was published in 1993.  
Employing the BSID-III in assessing development ensures an outcome of the 
presence or absence of developmental delay; it is therefore not diagnostic as to the 
cause of delay (Bayley, 2006).  This tool can be used to assess development in infants 
from one month to 42 months of age.  Development was assessed by administering 
three scales that focus on the following areas of development: cognition; language 
(receptive and expressive); and motor (fine and gross).  Once each area is assessed, 
a raw score is obtained for each scale.  The raw score is the sum of the number of 
items achieved in each scale.  Raw scores cannot compare performance between 
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scales, or compare a child with other children.  Raw scores are used to obtain derived 
scores, namely scaled scores and composite scores.    Scaled scores are derived 
from the total raw scores obtained according to age.  Scaled scores are scaled from 
one to 19 with a mean of ten and a standard deviation of three.  Composite scores are 
a transformation of a distribution of scores computed from the scaled scores.  
Composite scores range from 40 to 160, with a mean of 100 with a standard deviation 
of 15 (Bayley, 2006).  Although none of the BSID editions (I-III) have been normed on 
Zimbabwean children, the tool was employed for its superior ability to identify 
developmental delay as seen in many other studies in sub-Saharan Africa (Shead, et 
al., 2010; Potterton, et al., 2009b; Baillieu and Potterton, 2008; Van Rie, et al., 2008; 
McGrath, et al., 2006; Drotar, et al, 1997). 
 
3.6 Procedure 
 
All infant and mother pairs enrolled in this study were assigned a study number prior to 
assessment by the principal investigator so that all data were coded.  Data obtained 
from the mother and infant pairs in this study were collected at each site by the 
principal investigator and a research assistant at one time-point. 
 
On the day of assessment, the mothers of all infants were interviewed by the research 
assistant using the Maternal Interview (Appendix III) which obtained data of interim 
history (intercurrent illnesses, feeding, development and maternal health).  The 
information obtained from the mother regarding intercurrent illnesses was also used to 
assess whether the infant was in a healthy state to be assessed.  The mothers of any 
infants who had been ill within the past two weeks (recent illness) were asked to come 
back after the infant had been well for two weeks.  These mothers were provided with 
bus fare if the return date did not coincide with an existing appointment.   The research 
assistant recorded the following on the Data Collection Sheet (Appendix IV): infant’s 
anthropometric measurements (height, weight and head circumference) and 
immunisations; mother and infant CD4 counts and percentages (respectively) and viral 
loads; as well as all medications used by the mother and infant since pregnancy.  
These data were obtained from medical records and the child’s health card, where 
available.  The infant was then assessed by the principal investigator to obtain the 
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anthropometric measurements, as well as to assess for cognitive, language and motor 
development of the infant using the BSID-III. 
 
To ensure standardised assessment, each infant was assessed using the BSID-III 
whilst seated at a standard table and on their mother’s lap.  This ensured that they 
were able to access the toys when presented to them.  The mother was asked not to 
talk during the assessment, or to interact with the infant unless asked to by the 
principal investigator.  The principal investigator administered the scales in the 
following order: cognitive, language (receptive followed by expressive) and finally the 
motor scale.  Each assessment took approximately 40 minutes to administer.  Due to 
the ages of the infants assessed, there was no need to translate any scales.  
However, the research assistant helped with instructions to the mothers if needed. 
 
3.7 Data Analysis 
 
This study recruited 60 (28 HEI; 32 HEU) infants from six weeks to 12 months of age.  
This sample size was calculated using a 90% power calculation to detect a difference 
between the groups of 15 on the BSID-III when using a mean of 100 with a standard 
deviation of 15.   Conversion tables from the BSID-III were used to convert the raw 
scores into scaled scores and composite scores to provide individual quantitative 
scores and qualitative descriptions of development.  Descriptive statistics were 
employed to analyse the raw data.  Differences between the two groups were 
compared using independent t-tests: Chi-Squared Test and, Fischer’s Exact Test 
where values were less than five.  These data are presented in tables to show the 
means and standard deviations, frequencies and percentages.  Data were analysed 
using STATA (version 10.0 for Windows), where the level of significant for all statistical 
tests employed were set at p=0.05.   
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3.8 Conclusion 
 
This chapter has discussed the research setting, ethical considerations, study design, 
subjects, materials and measurements, the procedures used to collect data, and 
statistical methods employed to analyse the data. 
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CHAPTER 4: RESULTS 
 
This chapter will present the results of this study.  Sixty infants were enrolled in the 
study; 32 (53.33%) infants were HEU and 28 (46.67%) were HEI.  The data collected 
for the infants will be presented first, followed by that for the mothers.  Finally, the 
results of the developmental assessments will be presented.  Descriptive statistics 
were used to analyse the data and will be shown in tables with frequencies and 
percentages, or means and standard deviations.   
 
4.1 Infant Data 
 
4.1.1 Demographics 
 
The HEU and HEI groups were compared using a two sample t-test with equal 
variance.  Demographic data for the infants in each group are presented in Table 4.0.  
Relevant information was obtained from the Maternal Interview (Appendix III), the Data 
Collection Sheet (Appendix IV) and the BSID-III Record Form. 
 
Table 4.0 Infant demographic data 
Variable HEU n=32 HEI n=28 p-Value 
Females (%) 14 (50.00) 14 (50.00) 
0.628 
Males (%) 18 (56.25) 14 (43.25) 
 Mean SD Mean SD p-Value 
Age (months) 4.31 ±2.31 5.50 ±2.83 0.079 
Birth Weight (kg) 2.920 ±0.39 2.795 ±0.47 0.292 
 
Table 4.0 shows that there was no significant difference for gender, age or birth weight 
between each group thus showing that the groups were similar.  Birth weight could 
only be analysed from data of 31 HEU infants and 23 HEI infants, as there were 
missing data for six infants. 
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4.1.2 Anthropometric Data 
 
Anthropometric data (height, weight and head circumference) were recorded for each 
infant on the date that the developmental assessments using the BSID-III were done.  
Z-scores were calculated using WHO Anthro (Version 3.3.2).  A z-score of <-2.00 
indicates that infants are underweight (WAZ), stunted (HAZ), wasted (WHZ) or have 
microcephaly (HCZ). 
 
Table 4.1 Anthropometric data taken on the date of the developmental 
assessment 
Variable HEU HEI p-Value 
WAZ  -0.33 (±1.38) -2.67 (±1.64) <0.001 
HAZ -0.80 (±0.94) -2.28 (±1.54) <0.001 
WHZ 0.04 (±1.28) -1.49 (±1.61) <0.001 
HCZ 0.52 (±0.99) -0.92 (±1.56) <0.001 
(Values presented are means and standard deviations) 
 
Table 4.1 shows that there are statistically significant differences (p<0.001) between 
the groups for WAZ, HAZ, weight-for-height z-scores (WHZ) and head circumference-
for-age z-scores (HCZ).  HEI infants are underweight (-2.67) and stunted (-2.28) with 
smaller head circumferences (-0.92), however, their WHZ scores seem to be within 
normal limits (-1.49). 
 
4.1.3 Infant Medical Information 
 
Medical information for each infant was obtained from their medical records and Child 
Health Card and recorded on the Data Collection Sheet (Appendix IV).  Where 
information was not available in the records, missing information was extracted from 
the mothers’ report on their infants’ medical history during the Maternal Interview 
(Appendix III).  The findings are reported in Table 4.2 on the next page. 
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Table 4.2 Medical information for infants 
Variable HEU n=32 HEI n=28 p-Value 
ARV prophylaxis 
received 
Yes 31 (96.88%) 16 (57.14%) <0.001 
No 1 (3.13%) 12 (42.86%) 
Co-trimoxazole Yes 22 (68.75%) 28 (100.00%) <0.001 
 No 10 (31.25%) 0 (0.00%)  
Feeding Exclusive BF 25 (78.13%) 25 (89.29%) 0.038 
Mixed BF 0 (0.00%) 2 (7.14%)  
Formula 7 (21.88%) 1 (3.57%)  
Place of Birth Hospital/Clinic 28 (87.50%) 23 (82.14%) 0.721 
Home 4 (12.50%) 5 (17.86%)  
Illnesses Yes 2 (6.25%) 13 (46.43%) 0.001 
No 30 (93.75%) 15 (53.57%) 
Hospital Admissions Yes 1 (3.13%) 13 (46.43%) <0.001 
No 31 (96.88%) 15 (53.57%)  
Immunisations Yes 31 (100.00%) 26 (96.30%) 0.466 
No 0 (0.00%) 1 (3.70%)  
ARVs Yes 0 (0.00%) 10 (35.71%) N/A 
No 32 (100.00%) 18 (64.29%)  
(Values presented are frequencies and percentages) 
(N/A = not applicable) 
 
 
There is a statistically significant difference between the groups for ARV prophylaxis 
received, co-trimoxazole, feeding history, illnesses and hospital admissions.  More 
infants who received ARV prophylaxis were in the HEU group.  More children who had 
illnesses were in the HEI group and these infants also had more hospital admissions 
than the HEU group.    The entire HEI group received co-trimoxazole because they 
were HIV infected.  The feeding history shows that the HEU group were either 
exclusively breastfed or formula-fed.  None of these children were mixed fed unlike the 
HEI group. 
 
4.1.4 Infant Immunology and Virology 
 
CD4 counts and percentages show the state of the immune system where low CD4 
percentages (less than 25%) indicate severe immunosuppression in children.  The 
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viral load shows the amount of the virus in the body, where a viral load of more than 
five picogrammes of  the p24 protein (an indirect measure of virology) in the blood 
shows that the virus is replicating without control which indicates disease progression 
and poor prognosis (Mellors, et al., 1997).  Data for the HEI group were collected on 
each infant’s Data Collection Sheet (Appendix IV).  CD4 percentages and counts, are 
presented in Table 4.3 for infants in the HEI group.  Due to resource-constraints, only 
15 infants had CD4 percentages and four children had p24 values. 
 
Table 4.3 CD4 percentage, count and viral load for HEI infants 
Variable HEI 
CD4 Percentage n=15 17.91 (±9.97) 
CD4 Count n=14 1149.43 (±756.46) 
Viral Load (p24) n=4 293.20 (±443.84) 
(Values presented are means and standard 
deviations) 
 
Of the 15 infants with CD4 percentages, 12 (80%) had a CD4 percentage of less than 
25%, and only three (20%) had CD4 percentages of 25% and above.  The viral loads 
recorded for the four infants in this study were all above five copies per millilitre of 
blood.   
 
4.2 Maternal Data 
 
4.2.1 Maternal Demographics 
 
A Maternal Interview (Appendix III) was conducted with each mother to obtain data 
regarding the mother’s HIV status; her pregnancy, labour and delivery, and 
breastfeeding period; as well as socioeconomic background.  These data were used 
to identify any potential risk factors to the infant during pregnancy or delivery, as well 
as to determine each family’s socioeconomic status. 
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Table 4.4 Maternal demographics according to the status of their infants 
Variable HEU HEI p-Value 
Age (years) 29.88 (±5.87) 27.79 (±5.26) 0.155 
Level of Education completed 
(age) 
15.44 (±2.27) 14.86 (±2.19) 0.320 
Average number of people living 
in household 
4.91 (±1.49) 4.86 (±1.88) 0.911 
Earnings per month (USD) 164.53 (±194.38) 184.67 (±186.77) 0.762 
(Values presented are means and standard deviations) 
 
As seen in Table 4.4, there were no significant differences between the groups for 
maternal age, maternal education, average number of people living in the household 
or earnings per month. 
 
Earnings per month for each family could only be calculated using data from 34 
participants because 26 mothers (13 HEU infants; 13 HEI infants) refused to answer 
the question.   Table 4.5 presents these data. 
 
Table 4.5 Family earnings per month 
Earnings per month HEU n=19 HEI n=15 p-Value 
Extreme Poverty (USD1 per day) 3 (15.79%) 1 (6.67%) 0.583 
Poverty (USD2 per day) 3 (15.79%) 4 (26.67%) 
Above the Poverty Line 13 (68.42%) 10 (66.67%) 
(Values presented are frequencies and percentages) 
 
There is no statistically significant difference (p=0.583) between the two groups, which 
shows they are similar according to socioeconomic status.  It is also interesting to note 
that two-thirds of the participants are living above the poverty line (two US dollars per 
day).  Table 4.5 shows that six families in the HEU group and five families in the HEI 
group are living below the poverty line (extreme poverty, and poverty), and 23 families 
are living above the poverty line. 
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4.2.2 Maternal HIV History 
 
Information was obtained from medical records regarding each mother’s medical 
history.  This was recorded on the Data Collection Sheet (Appendix IV).  Where 
information was not available in the medical records, these data were obtained from 
each mother’s report during the Maternal Interview (Appendix III).  Table 4.6 presents 
these data. 
 
Table 4.6 Maternal HIV history according to the status of their infants 
Variable HEU n=32 HEI n=28 p-Value 
Awareness of 
HIV Status 
Before Pregnancy 24 (77.42%) 4  (14.29%) <0.001 
After Pregnancy 7  (22.58%) 24 (85.71%) 
ANC Booked 29 (90.63%) 19 (67.86%) 0.028 
Unbooked 3 (9.38%) 9 (32.14%) 
ART during 
pregnancy 
Yes 26 (81.25%) 1 (3.57%) <0.001 
No 6 (18.75%) 27 (96.43%) 
AZT during 
pregnancy 
Yes 3 (9.38%) 7 (25.00%) 0.165 
No 29 (90.63%) 21 (75.00%) 
sd-NVP at onset 
of labour 
Yes 5 (15.63%) 12 (42.86%) 0.024 
No 27 (84.38%) 16 (57.14%) 
Infections 
during 
pregnancy 
Yes 1 (3.13%) 2 (7.14%) 0.594 
No 31 (96.88%) 26 (92.86%) 
ART after birth Yes 29 (90.63%) 4 (14.29%) <0.001 
No 3 (9.38%) 24 (85.71%) 
Mode of 
Delivery 
NVD 24 (75.00%) 26 (92.86%) <0.001 
Elective C-Section 8 (25.00%) 0 (0.00%) 
Emergency 0 (0.00%) 2 (7.14%) 
(Values presented are frequencies and percentages) 
 
Table 4.6 shows that there were significant differences between the two groups with 
regard to: awareness of HIV status; ANC; ART received during pregnancy; and mode 
of delivery.  The difference between mothers who received ART after birth is also 
significant between the two groups (p<0.001) as only four mothers of HEI infants 
 
 
68 
 
received ART (one of whom started ART during pregnancy) at the time of data 
collection. 
 
Twenty-four (85.71%) of the HEI infants’ mothers only found out their HIV status after 
pregnancy which is statistically different (p<0.001) from the HEU group where the 
majority – 24 (77.42%) mothers, knew their status before pregnancy.  Twenty-nine 
(90.63%) mothers with HEU infants, the majority in this group, received ANC 
compared to only 19 (67.86%) mothers in the HEI group (p=0.028).  Only one mother 
(3.57%) in the HEI group received ART during her pregnancy compared to 26 
(81.25%) of mothers with HEU infants (p<0.001).   Twenty-six mothers (92.86%) in the 
HEI group had natural vaginal deliveries (NVD) and two (7.14%) had emergency 
caesarean (C-) sections which is statistically different from the 24 (75.00%) mothers in 
the HEU group who had NVD and eight (25.00%) who had elective C-sections 
(p=0.00).  Use of ART, elective C-sections and avoiding breastfeeding is the gold 
standard procedure for PMTCT during labour, delivery and birth, and the postnatal 
period (Sturt, et al., 2010).  
 
Twenty-seven (26 HEU infants, and one HEI infant) mothers received ART during 
pregnancy.  For the 33 mothers who did not receive ART during pregnancy, Table 4.7 
shows those who received prophylaxis, and the type given: 
 
Table 4.7 Type of prophylaxis given to mothers according to the status of 
their infants 
Prophylaxis HEU HEI p-Value 
None (%) 1 (16.67%) 13 (48.15%) <0.001 
AZT only (%) 0 (0.00%) 2 (7.41%) 0.214 
sd-NVP only (%) 2 (33.33%) 7 (25.93%) 0.069 
AZT + sd-NVP (%) 3 (50.00%) 5 (18.52%) 0.454 
(Values presented are frequencies and percentages) 
 
There is a statistically significant difference (p<0.001) between mothers receiving no 
ARV prophylaxis (none) and the HIV status of their infants.  Thirteen mothers did not 
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receive any prophylaxis (92.86%) and their infants are HEI.  However no significant 
differences occurred between the groups for those mothers who received: AZT only; 
or, sd-NVP only; or, both AZT and sd-NVP. 
 
4.2.3  Maternal Immunology and Virology 
 
CD4 Counts for 25 mothers of the HEU infants (seven unknown), and only for five 
mothers of the HEI infants (23 unknown) were used to calculate the means and 
standard deviations shown in Table 4.8 below.  Viral loads were unknown for eight 
mothers of HEU infants, and for all mothers of HEI infants.  Therefore, there are no 
conclusions that can be made from these data. 
 
Table 4.8 CD4 counts and viral loads for mothers 
Variable HEU HEI p-Value 
Mean SD Mean SD 
CD4 Count 358.76 (±143.10) 446.00 (±255.03) 0.2863 
Viral Load 11.59 (±44.56) NA NA NA 
(Values presented are means and standard deviations) 
(NA = not available) 
 
4.3 Developmental Analysis 
 
4.3.1 Cognitive, Language and Motor Development (Composite Scores) 
 
Developmental delay was calculated from the composite score (which is obtained from 
a scaled score which is computed from the child’s raw score according to their age).  A 
composite score of less than 85 represents delayed development, and a composite 
score of 85 and above, represents no delay.  The two groups were compared using 
Chi-Squared tests. 
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Table 4.9 Composite scores for cognitive, language and motor development 
Variable HEU HEI p-Value 
Cognitive Composite 100.31 (±12.75) 75.89 (±17.69) <0.001 
Language Composite 96.28 (±10.13) 77.18 (±16.33) <0.001 
Motor Composite 106.16 (±10.20) 79.71 (±20.91) <0.001 
(Values presented are means and standard deviations) 
 
Table 4.9 shows that there are statistically significant differences in cognitive, 
language and motor development between the HEU and HEI groups, where infants 
who are HEI are significantly delayed (<85) in all scales (p<0.001).  This is reported in 
more detail in sections 4.3.2-4 below. 
 
4.3.2 Cognitive Delay 
 
Eighteen HEI infants (64.29%) were found to have cognitive delay, where only one 
HEU infant had a cognitive delay (3.12%).  Thirty-one HEU infants (96.88%) showed 
no cognitive delay compared with ten HEI infants (35.71%).  Fischer’s Exact Tests 
were performed to analyse these data and showed significant differences in cognitive 
delay between the groups (p<0.001). 
 
4.3.3 Language Delay 
 
Seventeen HEI infants (60.71%) were found to have language delay, where only four 
HEU infant had a language delay (12.50%).  Twenty-eight HEU infants (87.50%) 
showed no language delay compared with 11 HEI infants (39.29%).  Fischer’s Exact 
Tests were performed to analyse these data and showed significant differences in 
language delay between the groups (p<0.001). 
 
4.3.4 Motor Delay 
 
Fifteen HEI infants (53.57%) were found to have motor delay, where no HEU infant 
had motor delay (0.00%).  Thirty-two HEU infants (100.00%) showed no motor delay 
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compared with 13 HEI infants (46.43%).  Fischer’s Exact Tests were performed to 
analyse these data and showed significant differences in motor delay between the 
groups (p<0.001). 
 
4.3.5 Developmental Delay in Months 
 
Developmental age for each infant was calculated using the raw score obtained from 
each scale (Cognition, Language and Motor) and Table B.7 from page 220 of the 
BSID-III Administration Manual (Bayley, 2006) (Appendix V).  In order to obtain the 
difference in months, and essentially a delay, the difference between the mean 
chronological age and the mean developmental age was calculated and these findings 
(in months) are recorded in Table 4.10 below: 
 
Table 4.10 Difference (months) between chronological age and developmental 
age 
Variable HEU HEI p-Value 
Cognitive 0.28 (±1.14) 2.21 (±2.04) <0.001 
Language RC 0.44 (±1.47) 2.75 (±2.25) <0.001 
EC 0.53 (±1.48) 2.36 (±2.64) 0.001 
Motor FM 0.09 (±0.96) 1.68 (±1.98) <0.001 
GM -0.28 (±1.05) 1.57 (±2.25) <0.001 
(Values presented are means and standard deviations) 
 
As seen in Table 4.10 all scales revealed statistically significant differences for the 
mean chronological age and the mean developmental age (months) between the HEU 
infants and the HEI infants (p≤0.0001).  HEI infants show a mean cognitive delay of 
2.21 months for cognitive development, 2.75 months for receptive communication 
(RC), 2.36 months for expressive communication (EC), 1.68 months for fine motor 
(FM) and 1.57 months for gross motor (GM) development. 
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4.3.6 Frequency of Infants According to Qualitative Descriptions of 
Composite Scores 
 
Infants were stratified according to qualitative descriptions from Table 6.4 in the BSID-
III Technical Manual (Bayley, 2006, p.114).  This table has been replicated, as seen in 
Table 4.11 below. 
 
Table 4.11 Qualitative descriptions of composite scores 
 
Composite or Composite Score Equivalent 
 
 
Classification 
 
 
130 and above 
 
Very Superior 
120-129 Superior 
110-119 High Average 
90-109 Average 
80-89 Low Average 
70-79 Borderline 
69 and below 
 
Extremely Low 
 
 
 
The below tables (Tables 4.12-14) show the frequencies and percentages according 
to the qualitative descriptions above for cognition, language and motor composite 
scores.  Fischer’s exact tests were performed to show statistical significance. 
 
Table 4.12 Frequency of infants according to qualitative descriptions - cognition 
 HEU n=32 HEI n=28 p-Value 
Extremely Low 1   (3.13%) 10 (35.71%) <0.001 
Borderline 0   (0.00%) 3 (10.71%) 
Low Average 3   (9.38%) 9 (32.14%) 
Average 18 (56.25%) 5 (17.86%) 
High Average 8 (25.00%) 1   (3.57%) 
Superior 2   (6.25%) 0   (0.00%) 
 
Table 4.12 shows that just over a third of the infants in the HEI group show extremely 
low cognition.  Only a fifth of these infants are considered to have cognitive scores of 
average and high average.  The inverse is true for the HEU group where the majority 
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of these infants, 28 (87.5%), have cognitive scores that fall in the average, high 
average and superior categories.  Only four (12.50%) HEU infants have scores that 
fall into low average or extremely low cognition.   The difference between the HEU 
group and the HEI group is statistically significant (p<0.001). 
 
Table 4.13 Frequency of infants according to qualitative descriptions - language 
 HEU n=32 HEI n=28 p-Value 
Extremely Low 0   (0.00%) 9 (32.14%) <0.001 
Borderline 4 (12.50%) 8 (28.57%) 
Low Average 2   (6.25%) 4 (14.29%) 
Average 23 (71.88%) 7 (25.00%) 
High Average 3   (9.38%) 0   (0.00%) 
 
Twenty-one (75.00%) of the HEI infants showed low average, borderline and 
extremely low language scores compared to only six (18.75%) infants in the HEU 
group as shown in Table 4.13 above.  There is statistically significant differences 
between the two groups (p<0.001) for language scores. 
 
Table 4.14 Frequency of infants according to qualitative descriptions - motor 
 HEU n=32 HEI n=28 p-Value 
Extremely Low 0   (0.00%) 9 (32.14%) <0.001 
Borderline 0   (0.00%) 3 (10.71%) 
Low Average 2   (6.25%) 5 (17.86%) 
Average 18 (56.25%) 9 (32.14%) 
High Average 7 (21.88%) 2   (7.14%) 
Superior 5 (15.63%) 0   (0.00%) 
 
Table 4.14 shows that motor ability in the HEU group is of average and above for 30 
(93.75%) infants compared to only 11 (39.28%) infants in the HEI group.  Five 
(15.63%) of infants in the HEU group show superior motor scores.  The difference 
between the groups is of statistical significance (p<0.001); the HEI group has the 
majority of  its infants in the low average, borderline and extremely low categories, and 
the HEU group has the majority of its infants in the average, high average and 
superior categories. 
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4.3.7 Subjective Measure of Developmental Delay 
 
In the Maternal Interview (Appendix III) mothers were asked to report whether their 
infant had the same, slower or faster development than children of the same age.  
However, it was not indicated to the mother as to which area of development she was 
commenting on.  Fischer’s exact tests were used to analyse the data after the 
composite scores had been categorised as: delayed (<85); normal (85-115); or, 
superior (116 and above). 
 
The following tables show statistical significance (p=0.00) when looking at cognition 
(Table 4.15), language (Table 4.16) and motor development (Table 4.17) of the infants 
and comparing it to the mother’s response. 
 
Table 4.15 Maternal observation when compared to cognitive score 
Cognitive Score Maternal Observation p-Value 
Same Slower Faster 
Delayed 5 (26.32%) 12 (63.16%) 2 (10.53%) <0.001 
Normal 28 (80.00%) 3   (8.57%) 4 (11.43%) 
Superior 5 (83.33%) 0   (0.00%) 1 (14.29%) 
(Values presented are frequencies and percentages) 
 
Table 4.16 Maternal observation when compared to language score 
Language Score Maternal Observation p-Value 
Same Slower Faster 
Delayed 6   (28.57%) 13 (61.90%) 2   (9.52%) <0.001 
Normal 31   (81.58%) 2   (5.26%) 5 (13.16%) 
Superior 1 (100.00%) 0   (0.00%) 0   (0.00%) 
(Values presented are frequencies and percentages) 
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Table 4.17 Maternal observation when compared to motor score 
Motor Score Maternal Observation p-Value 
Same Slower Faster 
Delayed 4 (26.67%) 11 (73.33%) 0   (0.00%) <0.001 
Normal 27 (72.97%) 4 (10.81%) 6 (16.22%) 
Superior 7 (87.50%) 0   (0.00%) 1 (12.50%) 
(Values presented are frequencies and percentages) 
 
The above tables (Tables 4.15-17) show that the majority of mothers are correct in 
identifying that their infant has: the same development (normal) and slower 
development (delayed) when compared to another child of the same age.  However, 
few mothers were able to identify that their infant was developing at a faster (superior) 
rate of development, but were still able to identify that there were no delays. 
 
4.4 Conclusion 
 
The findings from this study show that the two groups were well-matched for infant 
demographics, anthropometry at birth, maternal demographics, as well as 
socioeconomic status.   
 
Statistically significant differences were found in anthropometry and development 
between the HEI and HEU group.  The HEI infants had malnutrition, were stunted and 
had smaller head circumferences than infants who were HEU.  The BSID-III showed 
that the average developmental delay for the HEI group was approximately two 
months below their average chronological age for all scales (cognitive, receptive and 
expressive communication, and, fine and gross motor age).  The HEI group showed 
that 64.29% had cognitive delay, 60.71% had language delay and 53.57% had motor 
delay.   
 
In addition to using the BSID-III to identify developmental delay, each mother was 
asked during the Maternal Interview (Appendix III) how they thought their infant was 
developing.  The results showed that the majority of mothers were able to correctly 
indicate whether their child was developing at the same, or at a slower rate of 
development than children of the same age. 
 
 
76 
 
 
This study confirms that infants who are HIV-exposed and infected are at risk for 
developmental delay. 
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CHAPTER 5: DISCUSSION 
 
As a group, HEI infants performed worse than HEU infants on tests of cognitive, 
language and motor development.  These results are consistent with other studies 
from sub-Saharan Africa (Lowick, et al., 2012; Ruel, et al., 2012; Jelsma, et al., 2011; 
Shead, et al., 2010; Potterton, et al., 2009b; Baillieu and Potterton, 2008; Smith, et al., 
2008; Van Rie, et al., 2008; McGrath, et al., 2006; Drotar, et al., 1997; Boivin, et al., 
1995; Msellati, et al., 1993) and the more developed world (Rice, et al., 2012; 
Koekkoek, et al., 2008; Lindsey, et al., 2007; Foster, et al., 2006; Smith, et al., 2006; 
Llorente, et al., 2003; Blanchette, et al., 2001; Macmillan, et al., 2001; Chase, et al., 
2000; Pearson, et al., 2000; Smith, et al., 2000; Belman, et al., 1996; Pollack, et al., 
1996; Chase, et al., 1995; Gay, et al., 1995; Nozyce, Hittelman, et al., 1994; Mellins, et 
al., 1994; Condini, et al., 1991; European Collaborative Study, 1990). 
 
This chapter will justify the study design, discuss the results and compare the findings 
with studies that have been done previously.  It will also be useful to discuss the 
limitations, implications and recommendations for the development of future studies. 
 
5.1 Study Design 
 
This study investigated the difference in development of infants from six weeks to 12 
months of age who were HIV-exposed.  This age range was chosen as few studies in 
sub-Saharan Africa have looked at this age-group with certainty of HIV status 
(McGrath, et al., 2006).  The BSID-III was a suitable tool to assess development in this 
age-group as it is an individually administered instrument designed to measure 
developmental delay of infants and toddlers (Albers and Grieve, 2007).  It is also well-
known that the BSID has been employed for its sensitivity, validity and reliability in 
assessing development in many previous studies of children with HIV (Shead, et al., 
2010; Potterton, et al., 2009b; Baillieu and Potterton, 2008; Van Rie, et al., 2008; 
Lindsey, et al., 2007; Foster, et al., 2006; McGrath, et al., 2006; Llorente, et al., 2003; 
Blanchette, et al., 2001; Macmillan, et al., 2001; Chase, et al., 2000; Pearson, et al., 
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2000; Smith, et al., 2000; Drotar, et al., 1997; Belman, et al., 1996; Pollack, et al., 
1996; Chase, et al., 1995; Gay, et al., 1995; Nozyce, Hittelman, et al., 1994; Mellins, et 
al., 1994; Belman, et al., 1988; Epstein, et al., 1986; Ultmann, et al., 1985).  The 
authors are of the view that it was not necessary to translate the BSID-III into 
chiShona (local language in Harare) as the age-range of infants included in the study 
dictated predominate, non-verbal use of language. 
 
Given the young age of these infants, it was important to ensure that each infant’s 
mother was present at the assessment.  The presence of someone other than the 
mother could indicate that the child had experienced some form of trauma (orphan 
hood or inconsistent caregivers).  This may have introduced confounding variables, 
where delays in development may be attributed to risk factors of early child 
development (Baker-Henningham and Boo, 2010; Engle, et al., 2007).  Other studies 
with a similar age range failed to exclude infants if mothers were not present at 
assessment, and so, their results may show developmental delay due to risk factors 
other than HIV (Potterton, et al., 2009b; Baillieu and Potterton, 2008; McGrath, et al., 
2006; Drotar, et al., 1997; Boivin, et al., 1995; Msellati, et al., 1993). 
 
The Maternal Interview (Appendix III) was used to obtain information on the mother 
and infant’s HIV history, as well as obstetric history.  This was introduced into the 
study to identify other factors that may have contributed to neurodevelopmental 
impairment other than HIV (Abrams, et al., 2003).  Maternal health is also thought to 
influence the course of paediatric infection (Tovo, et al., 1994).  As timing of HIV 
infection is associated with differing clinical presentations in infants (McGrath, et al., 
2006), it was hoped that the information obtained from the mother’s HIV history would 
provide insight into the timing of HIV infection for each infant.  This information was 
also obtained to identify possible risk factors associated with MTCT of HIV as this 
would be useful in PMTCT (Kuhn and Stein, 1995).  The only conclusion that can be 
drawn from this information is that the majority of HIV-negative infants were born to 
mothers who were aware of their status before pregnancy and were receiving ART 
during pregnancy – the reverse was true for the HIV-infected group. 
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HIV-exposed infants who tested negative were assessed on the day of their DNA-PCR 
test to ensure that they were HIV-negative at the time of the BSID-III assessment.  
This was deemed necessary by the authors so as not to include infants who had 
undergone HIV-testing more than six weeks earlier, as continued breastfeeding in the 
HIV-exposed uninfected group provides further exposure to HIV infection (Coutsoudis, 
et al., 2004).  Not many other studies in sub-Saharan Africa with a similar age-range 
(Kandawasvika, et al., 2011; Drotar, et al., 1997; Boivin, et al., 1995; Msellati, et al., 
1993) report this concern when comparing their HIV-infected group with the uninfected 
group. 
 
5.2 Comparison of the Groups 
 
5.2.1 Demographics 
 
There were no significant differences between the groups for infant demographics 
(gender, age) or maternal demographics (age, level of education completed).  
Attempts were made using the Maternal Interview to compare the socioeconomic 
background (average number of people living in household, income) of the groups, 
however interpretation of these results should be made with caution as the author is 
not trained in this field of expertise.  The author acknowledges that the results may be 
confounded by variables which are difficult to control for, such as poverty, poor health 
and nutrition, and deficient care (Grantham-McGregor, et al., 2007).  However, the 
mothers and infants in this study were from similar geographic areas of Harare and 
accessed the same clinics, which may indicate similar socioeconomic backgrounds. 
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5.2.2 Anthropometric Measurements 
 
At Birth 
Although there has been less documentation, LBW is a risk factor for poor child 
development of cognition, behaviour and motor (Walker, et al., 2004; Gardner, et al., 
2003; Lui, et al., 2001; Grantham-McGregor, et al., 1998; Gorman and Pollitt, 1992; 
Villar, et al., 1984).  The groups were similar at birth according their birth weight where 
the HEU group had a mean weight of 2920 grammes (±390g) and the HEI group had a 
mean weight of 2795g (±470g).  Due to more than 80% of data missing for length and 
head circumferences at birth, it was impossible to compare the groups according to 
these variables.  Failure to obtain these measures might introduce discrepancies 
between the groups. 
 
At Assessment 
Abubakar et al (2009) report that WAZ and disease staging of children infected with 
HIV can be used in sub-Saharan Africa to identify those in need of psychomotor 
rehabilitation.  Poor WAZ has been associated with motor impairment in HIV-infected 
and uninfected populations (Abubakar, et al., 2009).  Pollack et al (1996) reported 
that: linear growth failure precedes cognitive and motor delay; growth failure is 
positively correlated with cognitive and motor delay; and onset of neurodevelopmental 
delay is earlier in infants with growth delay than in those without.  Acquired 
microcephaly, indicating impaired growth of the brain, was reported in early studies of 
paediatric HIV (Belman, et al., 1988; Belman, et al., 1985; Epstein, et al., 1985; 
Ultmann, et al.,1985). 
 
Significant differences in anthropometric measurements between the groups were 
observed in this study.  The HEI group were underweight, stunted and had smaller 
head circumferences.  The results of this study are similar to other studies which found 
that HIV-infected children had significant differences in anthropometric measurements 
compared to their uninfected peers (Potterton, et al., 2009b; Foster, et al., 2006; 
Pollack, et al., 1996). 
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5.2.3 Development 
 
Previous literature has reported a range of delays in children with HIV infection.  This 
study is no exception.  However, this study, like that by Van Rie and colleagues (2008) 
found that cognition was more affected than motor development.  More studies in sub-
Saharan Africa have shown motor delay to be more affected than cognitive delay 
(Shead, et al., 2010; Potterton, et al., 2009b; Baillieu and Potterton, 2008; Drotar, et 
al., 1997).  A possible explanation for the variation observed could be attributed to 
differences in child-rearing practices. 
 
Developmental assessment of children requires the use of specialised tools and 
training on administering these measures.  In the Maternal Interview (Appendix III) 
mothers were asked to comment on whether they thought their children were 
developing at the same, slower or faster rate than peers.  Sixty-three-point-one-three 
percent of mothers accurately identified a delay in cognition, 61.90% in language and 
73.33% in motor development.  Eighty percent, 81.58% and 72.97% of mothers 
accurately identified similar development to peers in cognition, language and motor 
development, respectively.  Few mothers were able to accurately identify superior 
development.  Limitations of these results apply as the mothers were not asked to 
specify which area of development they were commenting on. 
 
Developmental delay in this study was reported if an infant obtained a composite 
score of less than 85.  A composite score of less than 69 deemed the child to have 
extremely poor development (Bayley, 2006). 
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Cognitive Development 
Eighteen (64.29%) HEI infants had developmental delay in cognition.  Ten of these 
infants had extremely low cognition.  Only one (3.13%) HEU infant was delayed.  
Other studies in sub-Saharan Africa that used the BSID reported cognitive delay in 
HIV-infected children as the following range: 26% (Drotar, et al., 1997); 52% 
(Potterton, et al., 2009b); 60% (Van Rie, et al., 2008); and, 70% (Baillieu and 
Potterton, 2008). 
 
Cognition of HIV-infected children is likely to be more impaired than uninfected peers 
due to the neuropathological and structural changes associated with HIV infection of 
the CNS.  However, various other factors can contribute to cognitive delay in children 
such as stunting (Carba, et al., 2009; Walker, et al., 2007a; Alderman, et al., 2006), 
deficient care (Walker, et al., 2011) and duration of exclusive breastfeeding (Walker, et 
al., 2011; Clark, et al., 2006).  It is necessary to interpret the findings with caution as 
this study included children with stunting and was not able to measure the duration of 
exclusive breastfeeding due to the cross-sectional design.  Despite these limitations, 
HIV infection does not occur in isolation, and so while attempts were made to minimise 
confounding factors, this study provides an indication as to developmental delay in 
HIV-exposed infants. 
 
Language Development 
Development of language is complex.  It is reliant on both cognitive and motor 
development (Wolters, et al., 1997).  Language delay occurred in 17 (60.71%) of HEI 
infants, where nine of these infants showed extremely poor language development.  
Only four (12.5%) HEU infants were delayed in language acquisition.  Delay in 
language has been reported in only two studies in sub-Saharan Africa which used 
descriptive analysis of the data: 82.5% (Baillieu and Potterton, 2008); and 85% 
expressive language, 77% receptive language (Van Rie, et al., 2008).  This study 
found that the mean receptive language age (2.75 months delay ±2.25 months) of the 
HEI group was more delayed than their mean expressive language age (2.36 months 
delay ±2.64 months), when compared to their mean chronological age.  This finding is 
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different from other studies which found greater delay in expressive language in 
children with HIV infection (Van Rie, et al., 2008; Wolters, et al., 1997).  However 
these studies examined language development in older children. 
 
Motor Development 
Fifteen (53.57%) HEI infants showed developmental delay of motor function, where 
nine of these infants had extremely poor development.  No HEU infants were delayed 
in motor development.  The results on motor development in HIV-infected infants are 
comparable to other studies in sub-Saharan Africa: 29% (Van Rie, et al., 2008); 30% 
(Drotar, et al., 1997); 72% (Potterton, et al., 2009b); and, 85% (Baillieu and Potterton, 
2008).  The HEI group was underweight and stunted, therefore motor development 
could have been affected by these co-factors (Abubakar, et al., 2009; Pollack, et al., 
1996). 
 
5.2.4 Immunology, Virology and Antiretroviral Therapy 
 
It was not possible in this study to obtain CD4 counts and percentages and viral loads 
for all the mothers and HEI infants in this study.  Monitoring of HIV progression in 
Zimbabwe is limited to clinical and immunological assessment.  Virology is not 
routinely monitored in Zimbabwe.  The impact of ART was difficult to assess due to the 
study design.  Ten (35.71%) of the infants included in this study were receiving ART. 
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5.3 Limitations 
 
Every attempt was made to ensure that the authors minimised confounding variables 
as best as possible.  However, limitations in this study exist. 
 
 The BSID-III has not been normed, or validated on Zimbabwean children. 
 The cross-sectional design impaired the ability of this study to identify the timing 
of HIV transmission, as well as the impact of ART on development.  Timing of 
HIV transmission is associated with differing neuropathological and clinical 
manifestations of the disease. 
 Severity of HIV disease could not be obtained for mothers and HEI infants due 
to the lack of data on immunological and virological markers.  These data could 
have provided data to assist in determining the correlation between disease 
severity and developmental delay. 
 
5.4 Implications 
 
HIV-exposed infected infants are more at risk of cognitive, language and motor delay 
than HIV-exposed uninfected infants.  The implication of disability occurring in HIV-
infected children poses an additional burden for the family, as well as public health 
care systems.  With the advent of ART, and its increasing availability in sub-Saharan 
Africa, these infants are more than likely going to have similar life expectancies as 
their uninfected peers.  Despite this, the focus of HIV management is still centred on 
life-saving measures.  Healthcare professionals working in sub-Saharan Africa need to 
advocate chiefly for PMTCT to prevent paediatric HIV.  And, in the case of infants 
already infected, healthcare professionals and policy makers need to advocate for 
integrated, multidisciplinary management with timely identification and intervention.  
Without provision of allied health professionals (such as occupational therapy, speech 
and language therapy and physiotherapy) HEI children are likely to experience a 
significantly decreased quality of life as compared to their uninfected peers. 
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5.5 Clinical Recommendations 
 
 PMTCT needs to be scaled up in sub-Saharan Africa, as vertical transmission 
of HIV is avoidable. 
 In the case of infants infected with HIV then initiation of ART should be prompt 
after diagnosis 
 Early-intervention and multidisciplinary management of children infected with 
HIV should be common practice, and involve allied health professionals. 
 Utilisation of more efficacious regimens of ART for permeating the BBB so as to 
effectively halt viral replication of HIV in the CNS. 
 
5.6 Recommendations for Future Research 
 
 Conducting longitudinal studies at multiple sites in sub-Saharan Africa to obtain 
larger sample sizes. 
 Identifying timing of HIV infection as this is likely to impact on the severity of the 
disease.  This may potentially facilitate identification of distinctive clinical 
presentations. 
 Obtaining immunological and virological data for all mothers and infants. 
 Recording ARV/ART history for mothers and infants, as this variable is likely to 
impact on the course of the disease and the severity of impairment. 
 Developing a context-specific, global developmental screening tool to be used 
by nurses and doctors. 
 
The main conclusions which can be drawn from this study will be presented in the 
following chapter. 
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CHAPTER 6: CONCLUSION 
 
The purpose of this cross-sectional study was to determine developmental delay in 60 
HIV-exposed (28 infected, 32 uninfected) infants from six weeks of age to 12 months 
of age.  Cognitive, language and motor development was assessed using the BSID-III. 
 
The two groups were well-matched for infant demographics, anthropometry at birth, 
maternal demographics, as well as socioeconomic status.  Statistically significant 
differences were found in anthropometry and all domains of development between the 
HEI and HEU group.  This has been reported globally in studies on the development 
of HIV-infected children.  This study showed that HEI infants were malnourished and 
stunted and had smaller head circumferences than HEU infants.  It was also 
interesting to note that this study found that cognitive development was more affected 
than language and motor development, which is different to the majority of studies 
done in sub-Saharan Africa.  
 
This study demonstrates that infants who are HIV-exposed and infected are more at 
risk of developmental delay than HEU infants.  Timely identification of these children, 
as well as multidisciplinary intervention, is required to ensure that these children are 
able to reach their maximum developmental potential. 
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